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ABSTRACT 
 
MAHITA KADMIEL: Role of Receptor Activity Modifying Protein-2 (RAMP2)    
                               in endocrine physiology of female mice 
                           (Under the direction of Dr. Kathleen Caron) 
 
Receptor activity modifying proteins (RAMPs 1, 2, and 3) are single-pass 
transmembrane proteins that can regulate the trafficking, ligand-binding, and 
signaling of several G protein-coupled receptors (GPCRs). For example, 
biochemical studies have shown that RAMP2 interacts with calcitonin receptor-
like receptor (CLR), parathyroid hormone receptor (PTHR1) and calcitonin 
receptor (CTR).  However, the most well-characterized role of RAMP2 is in the 
regulation of adrenomedullin (AM; gene: Adm) binding to CLR (gene: Calcrl), and 
previous in vivo work from the Caron laboratory supports this canonical signaling 
paradigm.  Loss of RAMP2 causes embryonic lethality associated with failed 
lymphatic vascular development, which is a precise phenocopy of the defects 
seen in Adm-/- and Calcrl-/- mice. However, Ramp2+/- mice survive, and here we 
present the phenotypic analyses of Ramp2+/- female mice and Ramp2-/- 
placentas, many of which are distinct from the phenotypes observed in Adm and 
Calcrl mice. Haploinsufficiency of Ramp2 causes severe subfertility in female 
mice characterized by intrauterine growth restriction and postnatal lethality. 
Furthermore, Ramp2+/- female mice exhibit hyperprolactinemia, pituitary gland 
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hyperplasia, precocious mammary gland development, and skeletal 
abnormalities—phenotypes that are distinct from those observed in Adm+/- and 
Calcrl+/- mice. In addition, Ramp2-/- placentas have marked defects, including 
reduced labyrinth size, reduced cellularity and reduced proliferation of 
labyrinthine trophoblast cells.  Interestingly, loss of Ramp2 was also associated 
with reduced expression of the Pthr1 gene and protein in placental lysates, which 
is consistent with the previously described function of PTHR1 signaling in 
regulating trophoblast cell proliferation. Taken together, this work provides the 
first in vivo evidence demonstrating an essential role for RAMP2 in the female 
endocrine system.  The expanded range of phenotypes observed in the Ramp2 
gene targeted animals, compared to those seen in Adm and Calcrl animals, 
considerably extends the biological functions of RAMP2 beyond the canonical 
AM/CLR signaling pathway and supports an essential role for RAMP2 in PTHR1 
signaling.  Therefore, these studies provide novel physiological insights and 
potential pharmacological targets for the future development of RAMP2‑based 
therapies for the treatment of female endocrine disorders. 
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RAMPs 
Receptor activity modifying proteins (RAMPs) belong to a class of single-
pass transmembrane proteins that regulate the function of several G-protein 
coupled receptors. In mammals, there are three RAMPs, RAMP1, 2 and 3, 
identified to date. RAMPs were discovered in 1998, when McLatchie and 
colleagues ended the controversy among receptor biologists who studied the 
actions of calcitonin gene related peptide (CGRP) and adrenomedullin (AM) by 
showing that RAMP1 can translocate calcitonin receptor-like receptor (CLR) to 
the plasma membrane from the endoplasmic reticulum to form a functional 
receptor for CGRP (1). Later, sequence based analyses led to the discovery of 2 
additional RAMPs, -2 and -3 that when bound to CLR, formed receptors AM1 and 
AM2 for adrenomedullin, respectively. Therefore, based on the RAMP expressed 
in a given cell type, CLR can form three functional receptors for two different 
ligands, indicating that RAMPs can dictate ligand-binding specificity of GPCRs. 
Not surprisingly, this novel range of diversity of GPCRs created a paradigm shift 
in our understanding of GPCR pharmacology. 
GPCR-RAMP interactions 
Although RAMPs were discovered in the context of CLR, additional 
biochemical studies have been employed to identify several novel GPCR 
partners for RAMPs. All RAMPs are shown to interact with calcitonin receptor 
(CTR) to form a functional receptor for Amylin (2). Besides CLR and CTR, 
RAMP2 also interacts with parathyroid hormone receptor1 (PTHR1), glucagon 
receptor (GCGR), and the receptor for the vasoactive intestinal peptide (VPAC1) 
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(3). RAMP3 also interacts with the PTHR2 and the secretin receptor (SCTR) (4)  
These receptors belong to Family B of GPCRs—receptors with unusually long 
extracellular domains (ECD) that may form interfaces with the ECD of RAMP 
proteins.  However, not all family B GPCRs associate with RAMPs. Receptors 
such as the VPAC2, receptors for glucagon-like peptide, GLP1 and GLP2 and 
the receptor for growth hormone releasing hormone have been shown to not 
associate with any of the RAMPs (3). Moreover, RAMP interactions with GPCRs 
are not confined to the Family B GPCRs. Calcium sensing receptor (CaSR) has 
been shown to interact with RAMP1 and RAMP3, but not RAMP2 (5).  
Considering the range of GPCRs that associate with RAMPs and the wide 
expression pattern of RAMPs (57) in several tissues of the body, both in humans 
and in mice, it is highly likely that RAMPs have a much broader purpose than 
what is currently appreciated. Further studies are required to identify novel 
receptor partners for RAMPs. Importantly, future studies should address the 
physiological significance, if any, for both currently known and as-yet 
undiscovered GPCR-RAMP interactions. 
GPCR regulation by RAMPs 
RAMPs have been well-characterized in the context of the GPCRs- CLR 
and CTR. RAMPs have been shown to chaperone GPCRs from the endoplasmic 
reticulum to the plasma membrane. A classic example of this phenomenon is 
CLR, which is retained in the endoplasmic reticulum and cannot go to the cell 
surface on its own, but requires any one of the three RAMPs to do so (1). 
Another example is CaSR, which is chaperoned to the cell surface either by 
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RAMP1 or RAMP3, but not by RAMP2 (5). In contrast, certain GPCRs such as 
CTR can constitutively traffic to the plasma membrane without a RAMP, but the 
interaction with a RAMP changes the ligand binding affinity of the receptor. The 
paradigm of RAMPs altering ligand binding specificity is well-established and 
broadly applied.  For example, CLR bound to RAMP1 forms a receptor for 
CGRP, while CLR bound to RAMP2 or RAMP3 form AM1 and AM2 receptors, 
respectively. Another example is CTR, which binds to calcitonin in the absence of 
a RAMP, but binds to amylin when associated with either RAMP1, 2 or 3. RAMPs 
are also involved in recycling of GPCRs back to the cell surface following 
agonist-mediated receptor internalization. In particular, RAMP3, containing a 
PDZ-domain, has been shown to interact with proteins such as NHERF-1 and 
NSF to mediate the recycling of AM2 receptors (6-7).  
Finally, RAMPs can also alter GPCR signaling. The first observation of 
this phenomenon was seen with the VPAC1 receptor, which in the presence of 
RAMP2, enhanced phosphoinositide hydrolysis in COS-7 cells in response to the 
agonist, VIP (3). More recently, studies have shown that amylin receptors 
selectively modulated downstream signaling, including cAMP generation. 
Specifically, AMY1 (CTR/RAMP1) and AMY3 (CTR/RAMP3) receptors displayed 
robust induction of cAMP in response to AMY, compared to CTR alone, 
indicating that RAMPs can influence GPCR signaling (8). The numerous modes 
of regulation of GPCRs by RAMPs are summarized in Fig1. 
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Molecular basis of GPCR-RAMP interaction 
Considering the drug targetable potential of RAMPs, it is important to 
understand the interactions between GPCRs and RAMPs at the molecular level. 
Most of what we know about RAMP/GPCR interactions comes from studies 
performed with RAMP/CLR complex, mostly RAMP1/CLR. Early studies using 
chimeras of RAMPs revealed that the N-terminus of RAMPs plays a predominant 
role in determining receptor pharmacology by dictating ligand-binding specificity 
as well as for the interaction with the receptor (9-10). Evidence suggests 
asymmetric arrangement of CLR/RAMP1, where a CGRP receptor comprises of 
2 CLR molecules interacting with one RAMP1 molecule (11). Very little is known 
about the stoichiometry between GPCRs and RAMPs.  However, since most of 
the RAMP-interacting GPCRs belong to the Secretin family of GPCRs, a general 
opinion about the nature of RAMP-GPCR interactions can be gathered from 
structural studies on other members of the Secretin family. Secretin family of 
GPCRs consists of 15 peptide binding receptors, all of which have an N-terminal 
domain ranging from 100-160 residues, a juxtamembrane domain with seven 
transmembrane α-helices forming intervening loops, and an intracellular C-
terminal end. Intracellular signaling is initiated when the intracellular loops 
interact with G-proteins, predominantly through Gs coupled pathways for Secretin 
family GPCRs (12) . Studies that solved structures of receptors of GLP-1, PTH1, 
and CRF have shown that the ECD of GPCRs binds the C-terminus of the ligand.  
Moreover, the recently resolved crystal structures of a complex containing the 
ECD of hRAMP1 (13), a complex with ECD of human CLR/RAMP1 and a small 
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molecule antagonist (14), and the ECD of hRAMP2 (15) provide insight on 
GPCR-RAMP interaction and peptide binding. These structures revealed that the 
ECD of CLR was similar to the ECD of other members of the Secretin family of 
GPCRs. Of the three helices in RAMP1, αR2 and αR3 form an interface with the 
N-terminal helix of CLR by forming hydrophobic and electrostatic interactions 
(CLR residues: y49, Q45 and M42; RAMP1 residues: Y66, F93, H97, and F101).  
The findings from these structural studies are consistent with previous 
mutagenesis studies, where mutation of the key residues in RAMP1 resulted in 
poor cell surface expression of CLR/RAMP1 complex (16). The residues on 
RAMP1 that are crucial for interaction with CLR are also conserved in RAMP2 
(residues Y66 and F101).  
Based on the structural studies, it is speculated that the RAMPs bind to 
the C-terminal end of the peptide. In this aspect, the residues potentially 
responsible for peptide-binding are not conserved between all RAMPs, thereby 
determining ligand-binding affinity and/or specificity. For example, W74 of 
RAMP1 when substituted with its equivalent residue in RAMP2 (E101) and 
RAMP3 (E74) resulted in enhanced AM binding and potency. Contrastingly, an 
E101W substitution in RAMP2 and an E74W substitution in RAMP3 did not result 
in a CGRP receptor, but completely disrupted the function of AM1 receptors and 
attenuated the function of AM2 receptors.  
Lastly, the structure of the ECD of the complex containing CLR, RAMP1 
and an antagonist revealed three regions that interact with the ligand — a CLR 
binding region, an interface binding region, and a RAMP1 binding pocket. 
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Although the information obtained from these structures is specific to 
CLR/RAMP1 in complex with small molecules, this knowledge can be utilized to 
develop future therapeutic molecules. While challenging, future studies aimed at 
resolving GPCR-RAMP complex at the transmembrane (TM) region and the 
intracellular domain would provide insights on the role of TM of RAMPs in 
stabilization of its interaction with the receptor. In addition, understanding the role 
of the C-terminus of RAMPs would shed light on how RAMPs can influence 
trafficking and/or downstream signaling of GPCRs.  
Mouse models of RAMPs 
Since their initial discovery in 1998, the RAMP field has grown swiftly in 
terms of identifying the biochemical and pharmacological properties of RAMPs 
with a wide variety of GPCRs. However, what remains unclear, and is ultimately 
of high importance, is the physiological significance of RAMPs in normal and 
disease conditions.  Therefore, our laboratory as well as other groups have 
generated genetically engineered mouse models of all three RAMPs, with the 
ultimate goal of deleting, reducing or overexpressing RAMP proteins (17-23). 
Comparative phenotyping of all the available mouse models has enabled 
researchers in the field to uncover the most pertinent physiological functions of 
the RAMPs.  All the various mouse models of RAMPs are reviewed in detail in 
Chapter 3 (24). Briefly, loss of RAMP1 and RAMP3 led to no overt phenotypes. 
However, loss of RAMP2 is incompatible with life, indicating that the function of 
this RAMP cannot be compensated by the other two RAMPs. More recently, our 
work has shown that dosage of RAMP2 is critical for normal development of the 
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female endocrine system in mice (25). Taken together, genetically engineered 
mouse models of RAMPs have shed light on the physiological as well as 
clinically relevant roles of RAMPs.  
Disease relevance of RAMPs 
Ramp mRNA levels are differentially regulated in disease conditions such 
as heart failure (26-28), hypertension (29-30), kidney failure (31-32) and diabetes 
(32). Interestingly, RAMPs have been shown to be upregulated in normal 
pregnancy, suggesting a physiological function (33). Work from our laboratory, 
which is presented in Chapter 4 of this dissertation shows that loss of RAMP2 in 
the placenta results in phenotypes that are also observed in preeclampsia. 
RAMPs are also upregulated in hypoxic conditions (34-35), suggesting relevance 
in tumor biology. Taken together, the disease implications of RAMPs make them 
attractive drug targets.  
RAMPs as drug targets 
RAMPs diversify the receptor repertoire of GPCRs; based on their 
availability, different RAMPs enable the same GPCR to bind to more than one 
ligand. As a result, the GPCR-RAMP interface can be exploited to develop drugs 
that confer a high level of specificity. Considering that more than 50% of the 
drugs on the market target GPCRs, it is not surprising that the pharmaceutical 
industry has taken advantage of the drug-targetable GPCR-RAMP interface.  
Several chemical antagonists targeting the CLR-RAMP1 interface have been 
developed for the treatment of migraine and are currently undergoing clinical 
trials (36-37). This is only the beginning for RAMP-based therapeutics and as we 
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expand our knowledge of the physiological and pathophysiological roles of 
RAMPs, the scope of novel GPCR-RAMP targets will only increase further. The 
work presented in this dissertation sheds light on the physiological roles of 
RAMP2 and aims to serve as a tool in the development of RAMP2-based 
therapeutics.  
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Figure 1.1 RAMPs regulate GPCRs 
RAMPs regulate trafficking, ligand-binding and signaling of GPCRs. 
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UNDERSTANDING RAMPS THROUGH GENETICALLY ENGINEERED 
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ABSTRACT 
The family of receptor activity modifying proteins consists of three 
members, RAMP1, 2 and 3, which are each encoded by a separate gene and 
have diverse spatiotemporal expression patterns.  Biochemical and 
pharmacological studies in cultured cells have shown that RAMPs can modulate 
several aspects of G protein-coupled receptor (GPCR) signaling, including 
receptor trafficking, ligand binding affinity, second messenger signaling and 
receptor desensitization.  Moreover, these studies have shown that RAMPs can 
interact with several GPCRs other than the canonical calcitonin receptor-like 
receptor (CLR), with which they were first identified.  Given these expanding 
roles for RAMPs, it becomes interesting to question how these biochemical and 
pharmacological properties bear significance in normal or disease physiology.  
To this end, several gene targeted knockout and transgenic models have been 
generated and characterized in recent years.  Fortunately, they have each 
supported important roles for RAMPs during embryonic development and 
adulthood.  This chapter provides a comprehensive overview of the most recent 
findings from gene targeted knockout mouse models and transgenic over-
expression models, and gives special consideration to how comparative 
phenotyping approaches and conditional deletion strategies can be highly 
beneficial.  In the future, these genetically engineered mouse models will provide 
both insights and tools for the exploitation of RAMP-based therapies for the 
treatment of human diseases. 
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Introduction 
The family of mammalian receptor activity modifying proteins (RAMPs) 
offers an exciting opportunity to elucidate the pharmacological and biological 
complexities of G protein-coupled receptor (GPCR) signaling while also enabling 
the unique pharmacological manipulation of numerous GPCRs that are involved 
in a wide variety of physiological process and disease conditions.  The wide 
tissue distribution of RAMP proteins and their evolutionary conservation suggests 
that they have much broader functions than just mediating the ligand binding 
specificity of the calcitonin receptor-like receptor, through which the RAMPs were 
originally identified by Foord and colleagues (1).  In fact, numerous studies by 
several groups have demonstrated that RAMPs can functionally interact with at 
least 5 other receptors of the Secretin Family (38), the calcium sensing receptor 
(5) as well as the non-receptor cytoskeletal protein, alpha tubulin (39). Moreover, 
pharmacological and biochemical studies in cultured cell lines suggest that 
RAMPs can modify numerous aspects of GPCR signaling, including ligand 
binding, receptor desensitization, receptor trafficking and second messenger 
signaling and so they make attractive pharmacological targets (40). 
 These exciting and seemingly expanding functions for RAMP proteins also 
complicate our efforts to better understand the physiological significance of 
RAMPs in normal and disease conditions.  Therefore, our laboratory has 
employed a gene targeting approach to generate mouse models with absent 
and/or reduced expression of each RAMP and then comparatively phenotype the 
models to uncover the most pertinent physiological functions of the RAMPs.  
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Several other groups have also independently generated individual RAMP 
knockout mice so that the comparative evaluation of different mouse lines, 
genetic backgrounds and phenotypes can be extremely valuable.  Finally, the in 
vivo over-expression of RAMP proteins in specific cell types using conventional 
transgenic approaches has also been utilized to uncover new insights into RAMP 
biology.  Results and interpretations from these genetic animal models are 
summarized below. 
 However, we must remain cognizant of several confounding variables 
when trying to infer the function of RAMPs from genetic animal model 
phenotypes.  First, if the loss of a RAMP gene is incompatible with life, for 
example with RAMP2, then the assessment of loss-of-function effects during 
adulthood is precluded.  To overcome this barrier, sophisticated gene targeting 
approaches which can conditionally inactivate a gene either in time or in a 
specific tissue or cell type can be used, but this typically requires generation of 
additional mouse models and complex breeding schemes. Alternatively, the 
surviving haploinsufficient mice can be evaluated for phenotypes, but the 
phenotypes must be robust enough to be detected on a heterozygous 
background.  Secondly, because the gene expression of RAMPs is dynamically 
regulated in a spatio-temporal manner by a variety of stimuli and conditions, the 
physiological effects of loss or reduction in Ramp gene expression may not be 
obvious under basal conditions.  Therefore, challenging the animal models so 
that they are under appropriate physiological conditions which mimic the spatio-
temporal regulation of Ramp gene expression may be desirable.  Thirdly, as we 
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have learned from in vitro pharmacological studies, the RAMPs can interact with 
numerous GPCRs in a manner which is not always straightforward.  For 
example, association of RAMPs 1, 2 and 3 with the calcitonin receptor 
dynamically changes the relative affinity of the receptor for the amylin ligand (8), 
so that a functional knockout of one RAMP may be partially compensated for by 
the expression of other RAMPs with respect to amylin signaling.  As another 
example, association of RAMPs and receptors from different species can lead to 
marked differences in pharmacologcial profiles (41), so that the lessons learned 
from in vitro studies using combinations of reconstituted human, rat or other 
species receptors and RAMPs should be considered carefully when interpreting 
in vivo phenotypes of mouse models.  Finally, as is the case with most genetically 
engineered mouse models, the influence of genetic background on the observed 
phenotype plays an important role.  In our own studies, we have found drastic 
changes in the gene expression levels of RAMPs between different genetic 
backgrounds which directly translates to a different presentation of phenotype for 
the disrupted allele on different genetic backgrounds (Kadmiel, Fritz-Six & Caron; 
unpublished observation (25)). 
 Nevertheless, it is clear that genetically engineered animal models can 
provide useful and clinically-relevant insights into the broad functions of the 
RAMP family of proteins.  As we begin to exploit RAMPs for pharmacological 
manipulation of GPCRs, these models, as well as those generated in the future, 
will provide useful in vivo tools for the pre-clinical testing of relevant compounds. 
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RAMP1 
Gene targeted deletion of RAMP1 
The CLR-RAMP1 heterodimer makes a functional receptor for CGRP, a 
neuropeptide which plays important roles in the regulation of cardiovascular and 
immune systems.  A mouse line lacking the Ramp1 gene ubiquitously was 
generated utilizing the Cre-loxP strategy (42).  Although Ramp1-/- mice had no 
obvious abnormalities in their appearance, they had slightly elevated basal blood 
pressure with normal heart rate compared to wild type mice, as measured by carotid 
catheters under anesthesia. Experiments measuring the activity of the vasodilators 
αCGRP, acetylcholine and sodium nitroprusside were performed in Ramp1-/- and 
wild type mice to address the function of RAMP1 in mediating vasodilation.  Ramp1-/- 
and wild type mice exhibited similar responses to acetylcholine and sodium 
nitroprusside, but Ramp1-/- mice failed to respond to the vasodilatory effects of 
αCGRP.  These data demonstrate that the lack of a response to αCGRP in Ramp1-/- 
mice is not due to any abnormalities in the vascular smooth muscle cells or 
endothelial cells and confirm that the vasodilatory action of αCGRP is dependent on 
the availability of CLR-RAMP1 receptor complex.  Interestingly, Ramp1-/- mice had 
elevated levels of serum CGRP, which further confirms that in spite of the availability 
of the ligand, the lack of the functional receptor leads to dysregulation of 
vasodilation. Although CLR-RAMP1 receptor complex is defined as a CGRP 
receptor, little is known about the differential effects of the two isoforms of CGRP, 
αCGRP and ßCGRP, on this receptor. Responses to αCGRP and ßCGRP on the 
relaxation of aortic rings from Ramp1-/- and wild type mice demonstrated that CLR-
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RAMP1 serves as a receptor for both isoforms, but that the α-isoform elicits a 
stronger effect than the ß- isoform of CGRP.  In support of the promiscuous nature 
of RAMP-receptor pharmacology, differential responses to relaxation of the aortic 
rings to adrenomedullin in Ramp1-/- and wild type mice suggested that 
adrenomedullin may partially transduce signaling via CLR-RAMP1 receptor. 
Administration of lipopolysaccharide (LPS) in Ramp1-/- and wild type mice helped to 
elucidate an important function for CGRP in regulating inflammation (42). 
Interestingly, LPS-induced cytokine production and inflammation caused a 
remarkable increase in serum CGRP levels of Ramp1-/- mice compared to wild type 
mice. These data suggest a mechanism where CGRP, via the CLR-RAMP1 
receptor, carries out an anti-inflammatory role by suppressing the production of 
proinflammatory cytokines.   
Altogether, findings from the characterization of Ramp1-/- mice have 
confirmed the crucial role of RAMP1 in the CGRP signaling pathway, particularly in 
the cardiovascular and inflammatory processes. 
Transgenic overexpression of RAMP1 
A transgenic mouse line that expresses hRAMP1 primarily in the neurons 
and glia has been generated by Zhang et al (22)  Nestin/hRAMP1 mice express 
hRAMP1 RNA in the brain, trigeminal ganglion, spinal cord and dorsal root 
ganglion. Quantitative gene expression showed that the mRNA levels of 
hRAMP1 in the brain were 50% of the endogenous mouse Ramp1 expressed in 
neuronal tissues.  Therefore, the overall increase in RAMP1 mRNA expression is 
modest, but importantly not supra-physiological, in the brain and the trigeminal 
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ganglion of nestin/hRAMP1 transgenic mice.  As a consequence, increased 
production of hRAMP1 in the trigeminal ganglia enhanced CGRP-induced 
release of substance P from these neurons, leading to plasma extravasation and 
inflammation in subcutaneous tissues (such as paws and whisker pads). The 
effect of CGRP-triggered neurogenic inflammation could be blocked by the 
CGRP antagonist, CGRP8-37; further indicating that trigeminal RAMP1 is 
involved in CGRP-induced inflammation.  Importantly, the expression of hRAMP1 
mRNA exclusively in neuronal tissues, but not in subcutaneous tissues, confirms 
the involvement of trigeminal hRAMP1 in CGRP-evoked inflammation.  
Therefore, the finding that the availability of RAMP1 is rate-limiting for the actions 
of CGRP in the trigeminal ganglion opens a new dimension on understanding 
trigeminal pathologies, such as migraine, by the regulation of CGRP and its 
receptor, CLR/RAMP1. 
More recently, Chrissobolis et al characterized the protective effects of 
RAMP1 in the vasculature using a transgenic mouse that ubiquitously expresses 
hRAMP1 (20). Quantitative PCR in several tissues showed ubiquitous expression 
of hRAMP1 in these transgenic mice. The transgene did not affect the 
endogenous levels of mouse RAMP1 because the gene expression levels were 
not different when compared to the controls.  In vitro studies involving carotid and 
basilar arteries of the transgenic mice exhibited a robust response to CGRP-
mediated vasodilation, when compared to other vasodilatory agents such as 
adrenomedullin or acetylcholine, confirming the selective response of the 
hRAMP1 rich endothelium to CGRP. Additionally, in vivo studies exhibited 
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vasodilation of the cerebral arteries in a CGRP-specific manner in hRAMP1 
transgenic mice compared to controls.  In the same transgenic hRAMP1 mice, 
Sabharwal et al (21) have shown that these mice display an attenuated response 
to Ang II-induced hypertension, suggesting that increased expression of RAMP1 
is vasoprotective. More interestingly, when the carotid arteries of mice were 
treated with acetylcholine in the presence or absence of Ang II to test AngII-
mediated vascular dysfunction, hRAMP1 expression in transgenic mice 
abrogated the effects of Ang II on the vasculature.  This is a novel finding 
attributing the functional role of RAMP1 in Ang II mediated vascular dysfunction.   
As shown by Zhang et al, Chrissobolis and group also show that increased 
expression of RAMP1  displays selective and enhanced vascular response to 
CGRP, but not Adrenomedullin, thereby making the effect of CGRP RAMP1-
limited.   
RAMP2 
Gene targeted deletion of RAMP2 
Unlike Ramp1 and Ramp3 null mouse models which survive to adulthood, 
Ramp2-/- mice are embryonic lethal at mid gestation (17-18, 23).  These findings 
demonstrate that the endogenous expression of Ramp1 and Ramp3 are unable 
to compensate for the loss-of-function of Ramp2 in vivo.  Amazingly, comparative 
phenotyping on similar isogenic genetic backgrounds revealed that gene 
knockout mice for AM (43), Calcrl (44) and RAMP2 (17, 45) share a conserved 
phenotype consisting of mid-gestation embryonic lethality characterized by 
generalized edema.  The conservation of phenotypes between the AM, Calcrl 
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and Ramp2 knockout lines not only highlights the importance of AM signaling for 
embryonic survival but also provides the first genetic evidence to substantiate the 
RAMP-GPCR signaling paradigm, and specifically the function of the CLR-
RAMP2 complex, in vivo. 
Generalized edema has been reported in other knockout mice that encode 
for genes crucial for lymphangiogenesis (46).  Characterization of AM-/-, Calcrl-/- 
and Ramp2-/- mice, which were all generated and maintained on an isogenic 
129/S6-SvEv-TC1 background, revealed that the principal cause of the edema 
was due to defects in lymphatic vascular development (18).  The jugular lymph 
sacs of the Ramp2-/- mice were significantly smaller than those of their control 
littermates.  In vivo BrdU incorporation assays further demonstrated a reduced 
rate of lymphatic endothelial cell proliferation compared to blood endothelial cells 
in all mutant lines tested.  Electron microscopy studies showed that the junctional 
barrier of blood and lymphatic vessels remained intact, but that the lymphatic 
endothelial cells appeared thin and often necrotic in the Ramp2-/- mice.  In vitro 
studies showed that AM signaling, mediated through RAMP2-CLR receptors, 
causes an enhanced activation of the MAPK/ERK signaling cascade, which is 
essential for endothelial cell survival and driving normal developmental 
lymphangiogenesis.  Because these studies, and findings from other groups, (47-
49) show that the expression of the Calcrl and Ramp2 genes is regulated by the 
lymphatic-specific transcription factor, Prox1 (47, 50), their expression is 
preferentially higher in lymphatic endothelial cells compared to blood endothelial 
cells.  Other cardiovascular defects in the Ramp2-/- embryos, which are also 
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present in the Adm (43) and Calcrl (44) null models, include thin vascular smooth 
muscle walls and small hearts with thin compact zones and disorganized 
ventricular trabeculae.  Together, these data identify a previously unrecognized 
role for RAMP2-mediated AM signaling in the development and function of the 
cardiovascular system and highlight the importance of CLR-RAMP2 signaling as 
a pharmacologically-tractable regulator of lymphatic proliferation. 
Ichikawa-Shindo et al. have also reported an independent line of Ramp2 
null embryos which were generated by global CAG-Cre driven excision of a 
floxed Ramp2 allele (23). These animals also demonstrated extensive 
generalized edema and pericardial effusion.  Ultrastructural analysis revealed 
defects in blood endothelial and vascular smooth muscle structure resulting in 
the presence of occasional hemorrhagic plaques. Using RNA lysates isolated 
from whole embryo extracts, significant reductions in the expression of 
endothelial adhesive genes was shown in Ramp2-/- mice compared to wild type 
controls, suggesting that the expression of Ramp2 is required for maintaining the 
blood vessel barrier. The subtle phenotypic differences between the two 
independent Ramp2 null mouse strains could be influenced by the different 
genetic backgrounds.  Importantly, the lymphatic and blood vascular defects are 
not mutually exclusive and actually shed greater insights into the complexity of 
and interplay between the blood and lymphatic vascular systems in maintaining 
tissue fluid balance (51). 
The embryonic lethality of Ramp2 global knockout mice precludes the 
study of RAMP2 loss-of-function in adult animals, but heterozygote animals 
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expressing half the normal levels of Ramp2 have been useful to study.  Ramp2 
heterozygous females on an SvEv129/S6 genetic background have severely 
reduced fertility with litter sizes approximately one third of wild type mice and 
other isogenic RAMP models (17).  While reduced fertility is also a hallmark 
feature of the AM+/- female mice, (52-53) the fertility defects of the Ramp2+/- 
females is much more prominent and severe, and in fact contributes to difficulties 
in maintaining the strain.  Our most recent studies suggest that the fertility 
defects can be attributed to marked endocrine imbalances in the hypothalamic-
pituitary axis which are not observed in the AM+/- model (M. Kadmiel & K. Fritz-
Six, unpublished observations, (25)).  Therefore, a divergence in phenotypes 
between the Ramp2+/- and AM+/- mice (all maintained on an identical genetic 
background), suggests that RAMP2 may have broader in vivo roles beyond its 
requirement for generating an AM receptor with CLR.  Consistent with our 
previous findings, a modest genetic reduction in Ramp2 had no effect on basal 
blood pressures or heart rates of conscious male or female mice, as measured 
by the tail cuff method (17). 
The Ramp2 heterozygote mice reported by Ichikawa-Shindo and 
colleagues also survived to adulthood, but unlike the Dackor et al Ramp2+/- mice 
these animals showed modest increases in basal systolic blood pressure, as 
measured in anesthetized animals using carotid artery catheters (23). Consistent 
with the canonical paradigm of RAMPs regulating CLR’s ligand binding 
specificity, the Ramp2+/- mice showed a markedly reduced vasodilatory response 
to AM treatment, but not to calcitonin gene related peptide (CGRP).  In a series 
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of elegant in vivo angiogenesis assays, the Ramp2+/- mice also revealed a 
reduced angiogenic response to VEGF, decreased neovascularization and 
increased in vivo vascular permeability in the footpad, skin and brain.  These 
studies, which are consistent with the discoveries made in the global Ramp2 
knockout embryos, highlight the importance of RAMP2-mediated signaling in 
regulating pathological angiogenesis and vascular permeability. 
Transgenic overexpression of RAMP2 
The effects of overexpression of RAMP2 in vivo have been investigated 
using a transgenic approach in which Ramp2 was overexpressed in smooth 
muscle, under the control of an α-actin promoter (54). Consistent with a modest 
role for RAMP2 in regulating basal blood pressures, the Ramp2 transgenic mice 
had mean arterial blood pressures and heart rates that were indistinguishable 
from their wild type littermates.  As expected, the Ramp2 transgenic mice 
exhibited potent and selective responsiveness to vasodilatory peptides.  For 
example, while AM treatment of Ramp2 transgenic mice enhanced vasodilation 
leading to increased stroke volume and reduced end-systolic pressure compared 
to similarly treated wild type animals, the administration of CGRP did not result in 
appreciable differences between the Ramp2 transgenic mice and wild type 
animals.  These data support a principal physiological function of RAMP2 in 
mediating the vasodilatory effects of AM in vascular smooth muscle cells.  The 
Ramp2 transgenic animals also showed increased inflammatory fluid 
extravasation after subcutaneous injection of substance P with co-treatment of 
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AM, but not with CGRP co-treatment, again supporting an important role for 
CLR-RAMP2 mediated regulation of tissue fluid balance. 
RAMP3 
Gene targeted deletion of Ramp3 
Ramp3 null mice survive to adulthood without any obvious developmental 
problems (17).  Basal blood pressures and heart rates are unaffected by the loss 
of Ramp3, and both male and female mice reproduce normally compared to their 
wild type littermates.  Despite the fact that global Ramp3 null mice exhibit normal 
food and water intake, they suffer from markedly reduced body weights after 
approximately 6 months of age.  Although the mechanisms underlying this 
phenotype are not yet understood, the age-dependent lean phenotype did not 
affect health or longevity up to 18 months of age. 
Lessons learned from comparative phenotyping 
A summary of the most well-characterized phenotypes discovered in 
genetic RAMP mouse models is provided in Table 1.  Characterization of any 
individual RAMP mouse model reveals important information about RAMP 
biological functions in vivo.  Comparing agonist activity in RAMP mice has 
provided direct in vivo evidence that RAMPs covey specificity for different 
ligands, such as AM and CGRP under physiological conditions.  For example, 
AM treatment, but not CGRP, shows potent effects on vasodilation and 
inflammation in RAMP2 animals, while CGRP treatment, but not AM, reveals 
physiological effects in Ramp1 transgenic mice. 
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A comparative approach to phenotyping between models can also provide 
powerful information, as long as the comparisons are performed on similar or 
identical genetic backgrounds.  Conservation of phenotypes between genetic 
RAMP models and genetic models of their putative ligands (for example, the 
conserved phenotypes of Adm, Calcrl and Ramp2 mice) can reveal 
physiologically important signaling paradigms that can be exploited for disease 
treatment or therapies.  On the other hand, highly divergent or unexpected 
phenotypes in the genetic RAMP models can reveal previously unrecognized 
roles for RAMPs in mediating the signaling of other ligands and receptors. 
It is also this direct comparison of RAMP models that allows us to better 
understand compensatory effects of the RAMPs for one another.  For example, 
embryonic lethality of the Ramp2 null mice demonstrates that loss of RAMP2 
cannot be compensated for by other RAMP family members, either because they 
are not expressed in the appropriate place and/or time or because RAMP1 and 
RAMP3 have non-redundant functions with RAMP2.  In contrast, global loss of 
either RAMP1 or RAMP3 does not affect survival, perhaps because the 
expression of other RAMPs compensates for their absence.  More definitive 
answers to these compensatory paradigms can come from careful evaluation of 
homeostatic responses in gene expression and protein expression of RAMPs in 
specific cells and tissues (57), but we are currently hindered by the lack of 
effective, commercially available murine antibodies for RAMP proteins.  
Finally, much can be gained from directly comparing phenotypes between 
gain-of-function and loss-of-function alleles for each RAMP model.  The 
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prediction is that altering the genetic dosage of a RAMP will result in a range of 
phenotypes.  In fact, studies on the angiogenic and permeability effects of 
RAMP2 in both transgenic and gene targeted models provides an elegant 
example of the strength of this comparative phenotyping approach.  In the future, 
additional animal models which expand our repertoire of both spatial and 
temporal manipulation of RAMP gene expression will continue to shed new 
insights in the physiological functions of RAMP proteins in normal and 
pathological conditions and potentially elucidate processes in which the 
pharmacological manipulation of RAMPs may be beneficial for treating human 
disease. 
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     Comparative Phenotyping of RAMP  Mouse Models
RAMP1     
-/- 
RAMP1 
TG
RAMP2      
-/- 
RAMP2 
+/- 
RAMP2 
TG
RAMP3       
-/-
Survive to Adulthood Yes Yes No Yes Yes Yes
Altered Blood Pressure Yes N/A N/A Yes/No Yes No
CGRP Relaxation Response
α=Enhanced                   
β=Normal
N/A N/A Normal Normal N/A
AM Relaxation Response Reduced N/A N/A Reduced Enhanced N/A
Inflammation/Fluid 
Extravasation basally #
Enhanced  
(LPS)
N/A N/A
Enhanced 
(histamine)
Normal 
(Substance P)
N/A
Inflammation/Fluid 
Extravasation with CGRP Tx
N/A Enhanced N/A N/A Reduced* N/A
Inflammation/Fluid 
Extravasation with AM Tx
N/A N/A N/A N/A Enhanced* N/A
Fertility Defects No No N/A Yes/No No No
Body Weight Defects No No N/A No No Yes
# Inflammatory treatment 
indicated in parentheses
*coinjected 
with SP
 
Table 1.1 Comparative phenotyping of RAMP mouse models 
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CHAPTER 3 
 
HAPLOINSUFFICIENCY OF RECEPTOR ACTIVITY-MODIFYING PROTEIN-2 
(RAMP2) CAUSES REDUCED FERTILITY, HYPERPROLACTINEMIA, 
SKELETAL ABNORMALITIES AND ENDOCRINE DYSFUNCTION IN MICE 
(25) 
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ABSTRACT 
Receptor activity-modifying protein-2 (RAMP2) is a single-pass 
transmembrane protein that can regulate the trafficking, ligand binding, and 
signaling of several G protein-coupled receptors (GPCR). The most well-
characterized role of RAMP2 is in the regulation of adrenomedullin (AM) binding 
to calcitonin receptor-like receptor (CLR), and our previous studies using 
knockout mouse models support this canonical signaling paradigm. For example, 
Ramp2-/- mice die at midgestation with a precise phenocopy of the AM-/- and 
Calcrl-/- mice. In contrast, Ramp2+/- mice are viable and exhibit an expanded 
variety of phenotypes that are distinct from those of Calcrl+/- mice. Using 
Ramp2+/- female mice, we demonstrate that a modest decrease in Ramp2 
expression causes severe reproductive defects characterized by fetal growth 
restriction, fetal demise, and postnatal lethality that is independent of the 
genotype and gender of the offspring. Ramp2+/- female mice also exhibit 
hyperprolactinemia during pregnancy and in basal conditions. Consistent with 
hyperprolactinemia, Ramp2+/- female mice have enlarged pituitary glands, 
accelerated mammary gland development, and skeletal abnormalities including 
delayed bone development and decreased bone mineral density. Because 
RAMP2 has been shown to associate with numerous GPCRs, it is likely that 
signaling of one or more of these GPCRs is compromised in Ramp2+/- mice, yet 
the precise identification of these receptors remains to be elucidated. Taken 
together, this work reveals an essential role for RAMP2 in endocrine physiology 
 30 
 
and provides the first in vivo evidence for a physiological role of RAMP2 beyond 
that of AM/CLR signaling. 
Introduction  
Receptor activity modifying proteins (RAMP) are single pass 
transmembrane proteins that can influence G protein-coupled receptor (GPCR) 
pharmacology by either altering the cell-surface trafficking of receptors, dictating 
ligand-binding specificity, regulating receptor desensitization, for modulating 
second messenger signaling (38). There are three mammalian RAMPs (RAMP1, 
-2, and -3), each encoded by a separate gene. The RAMPs were originally 
identified and characterized because they could potentiate the translocation of 
the calcitonin receptor-like receptor, (CLR) from the endoplasmic reticulum to the 
plasma membrane (1). In addition, each RAMP was shown to associate with 
CLR and change its ligand-binding affinity for different peptide ligands (1). For 
example, if CLR associates with RAMP1, then a functional receptor for calcitonin 
gene related peptide is formed, but if either RAMP2 or RAMP3 associates with 
CLR, then a functional receptor for Adrenomedullin (AM) is made. Therefore, the 
spatial and temporal expression of RAMP determines the cell surface expression 
and receptor pharmacology of RAMP-interacting GPCRs. 
Importantly, this added level of receptor complexity offers unique 
opportunities for the design of small-molecule compounds and drugs that are 
specifically targeted to the RAMP-receptor interface. For example, BIBN4096BS 
(olcegepant), MK-0974 (telcagepant), and MK-3207 are nonpeptide, small-
molecule antagonists that have clinical efficacy in targeting the CLR-RAMP1 
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interface to inhibit the functions of calcitonin gene-related peptide in migraine 
pain (55-58). Whether the RAMP-receptor paradigm can be exploited for 
pharmacological drug targeting of other GPCRs remains to be determined, but is 
currently hindered by our lack of knowledge regarding other physiologically 
relevant GPCRs that functionally associate with RAMPs. 
 The broader cell and tissue expression pattern of RAMPs compared with 
that of CLR and its ligands suggests that RAMPs are likely to interact with other 
GPCRs and modulate their properties. Indeed, numerous studies have 
demonstrated that the calcitonin receptor preferentially binds amylin, rather than 
calcitonin, when the receptor is associated with any of the three RAMPs. 
Moreover, in vitro biochemical studies in which the subcellular trafficking of 
overexpressed, fluorescently labeled RAMP is changed by receptor 
overexpression suggest that many other GPCRs functionally interact with 
RAMPs. These include several members of the class II GPCR: the PTH 
receptors (PTHR) 1 and 2, the vasointestinal peptide/pituitary adenylate cyclase-
activating peptide 1 (VIP/VPAC1) receptor, the glucagon receptor (3), and more 
recently the secretin receptor (4). Bouschet and colleagues also showed that a 
class III GPCR, the calcium-sensing receptor (CaSR), requires RAMP for 
efficient cell surface expression in transfected clonal cells (5). However, it 
remains largely unclear whether these in vitro interactions have any physiological 
relevance either in normal or pathological conditions. 
To address this gap in our knowledge, we have undertaken a phenotype-
driven approach to identify the physiologically relevant functions of RAMPs, and 
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ultimately their GPCR partners, by generating and characterizing gene knockout 
mice for each of the three mammalian Ramp genes. The overt phenotypes of 
various mouse models of RAMPs, including those generated by others, has 
recently been reviewed (24). Here, we describe a constellation of endocrine-
related phenotypes that are present in Ramp2+/-   mice, but are notably absent in 
mice heterozygous for the gene encoding CLR. Therefore, these data provide in 
vivo evidence for an important role of RAMP2 in endocrine physiology and 
extend the physiologically relevant functions of RAMP2 beyond the canonical 
CLR paradigm. 
Materials and Methods 
Animals 
Mice with a targeted deletion of Ramp2 were generated and characterized 
as described previously (17). Briefly, chimeric mice with Ramp2 gene targeted 
were generated using targeting vectors and embryonic stem cells of the 
SvEV129/6-TC1 background. Isogenic colonies were established by breeding 
chimeric male mice with SvEV129/6-TC1 female mice to generate SvEv- 
Ramp2+/- mice. We previously published that subfertility seen in SvEv-Ramp2+/- 
mice is completely rescued by backcrossing to the C57BL6 background (18). To 
obtain F2-Ramp2+/- mice, we bred SvEv-Ramp2+/- mice to C57BL6 wild-type mice 
to generate F1-hybrid offspring. F1 siblings heterozygous for Ramp2 were 
intercrossed to yield F2-Ramp2+/-. Genotyping was performed by PCR using a 
three-primer-based approach: primer 1, 5’-TCTGTCTGGATGCTGCCTTGC-3’; 
primer 2, 5’- GAAGTCAGGCAGTCAGGGTTG-3’; and primer 3, 5’-
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GACGAGTTCTTCTGAGGGGA-3’. Primers 1 and 2 amplified a 900-bp wild-type 
fragment, whereas primers 1 and 3 amplified a 650-bp targeted fragment. For 
timed matings, crosses were established, and the morning of vaginal plug 
detection was considered as E0.5day. Control animals were wild type with similar 
age, gender, and genetic background. All experiments performed on animals 
were approved by the Institutional Animal Care and Use Committee of The 
University of North Carolina at Chapel Hill. 
Serum hormone measurements 
Serum was collected by mandibular vein bleed at 0600 h where the light 
cycle was from 0700–1900 h. Prolactin and GH were assayed from serum by RIA 
by A. F. Parlow at the National Hormone and Peptide Program (Torrance, CA). 
Serum for calcium measurement was collected at 1000 h and was processed at 
the Animal Clinical Chemistry and Gene Expression Laboratories core facility at 
the University of North Carolina at Chapel Hill. 
Antibodies 
 The antibodies used in this study were obtained from National Institute of 
Diabetes and Digestive and Kidney Diseases and are the following: mouse 
prolactin (AFP-131078), mouse GH (AFP5672099), rat β-TSH (AFP-1274789), 
rat ACTH (AFP-156102789), rat β-LH (AFP-C697071P), and rat β-FSH 
(AFP7798-1289). Corresponding fluorescent secondary antibodies were 
purchased from Jackson ImmunoResearch (West Grove, PA). Nuclei were 
stained with Hoechst 33258 dye (Sigma-Aldrich, St. Louis, MO). 
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Histology and immunofluorescence microscopy 
 
Tissues were fixed in 4% paraformaldehyde, cryoprotected in 30% 
sucrose, embedded in OCT (Tissue-Tek), and cryosectioned at 8–10 µm. For 
immunostaining, sections were rehydrated in PBS, permeabilized in 0.2% Triton 
X-100, blocked in 4% BSA, and incubated in primary antibody overnight. After 
washing, sections were incubated in secondary antibody for 1–2h, washed, and 
mounted for imaging. Images were acquired on a Nikon E800 microscope with a 
Hamamatsu ORCA-ER charge-coupled device camera with Metamorph software 
(Molecular Devices Corp., Sunnyvale, CA) and processed with Photoshop. 
Pituitary gland volume and density measurements 
 
 Pituitary volume was calculated from two-dimensional images by making 
the assumption that the parameter of depth is proportional to the parameter of 
height for an ellipsoid shape. For measurement of pituitary cell density, cells 
were manually counted in 4’,6-diamidino-2-phenylindole-stained sections and 
represented as number of cells per square millimeter.  
RNA extraction, cDNA synthesis, and quantitative RT-PCR analyses 
 RNA was extracted using the Trizol method following the manufacturer’s 
protocol (Ambion, Austin, TX). Isolated RNA was deoxyribonuclease treated and 
reverse transcribed using the Moloney murine leukemia virus reverse 
transcriptase (Invitrogen, Carlsbad, CA), and gene expression was measured by 
MX3000 Q-PCR machine from Stratagene (Santa Clara, CA). All the primer-
probe sets used in this study were TaqMan probes purchased from Applied 
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Biosystems (Carlsbad, CA). mGAPDH was used as a normalizing gene, and the 
∆∆CT method was used to analyze the relative levels of gene expression (63). 
Mammary gland whole mounts 
 Mouse mammary glands were collected for whole-mount analysis. Fourth 
inguinal glands were carefully dissected, placed on a glass slide, air dried for 5 
min, and fixed overnight in Carnoy’s solution (three parts absolute ethanol and 
one part glacial acetic acid) and stained in Carmine alum (0.2% carmine dye and 
0.5% aluminum potassium sulfate) overnight. Slides were destained in 70% 
ethanol containing 2% HCl until the background was minimal and then 
dehydrated in increasing concentrations of ethanol. Toluene was used to defat, 
and the slides were mounted with Permount. Mammary gland branch points were 
manually scored in two images per animal along three major ducts that 
surrounded the lymph node within a 30-mm2 area. Terminal end buds located 
along a 5-mm length of a major peripheral duct were counted. 
DEXA densitometry 
 DEXA (Lunar PIXImus densitometer) was used to measure bone mineral 
density and content of right femurs. In vivo DEXA scans were performed by 
anesthetizing animals with tribromoethanol and laying the animal flat on the 
DEXA machine. 
Micro-CT 
 Micro-CT was performed to analyze femurs and vertebrae as described 
previously (59). Briefly, femurs were fixed, dehydrated, and scanned using a 
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high-resolution x-ray source to generate three-dimensional (3D) reconstructions. 
Virtual transverse sections at the mid-diaphysis of the femur 3D reconstructions 
were made that revealed the cortical and trabecular bone architecture. 
Statistical analyses 
 All quantitative analyses were performed using unpaired, two-tailed 
Student’s t test, unless otherwise specified. Data are represented as SEM unless 
indicated otherwise. Differences were considered significant when the P value 
was <0.05. 
Results 
Genetic reduction of maternal Ramp2 causes fetal loss throughout 
pregnancy 
We have previously shown that Ramp2-null embryos exhibit interstitial 
edema due to defective lymphangiogenesis and die at midgestation [embryonic d 
14 (E14.5)] on either a 129SvEV/S6 or an F2-129SvEv/S6-C57BL6 genetic 
background (18). We have also noticed that haploinsufficient Ramp2+/-  mice on 
a 129SvEv/S6 background survive to adulthood, but have extremely small litter 
sizes, worse than what would be predicted from the Mendelian loss of Ramp2-/- 
embryos (17). To determine the gestational age of fetal loss, we established 
natural timed matings between SvEv-Ramp2+/-  parents and scored the following: 
1) number of viable embryos at various gestational ages beyond implantation, 2) 
number of live pups at birth, and 3) number of live pups at weaning. These data 
were then compared with data obtained from crosses between wild-type SvEv 
parents. As shown in the gray dashed line of Fig.3.1A, wild-type SvEv 
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intercrosses maintained within our animal colony resulted in average litter sizes 
that are consistent with our previously published observations and those reported 
forathea129SvEv/S6-Taconicalinea(14)a(www.taconic.com/wmspage.cfm? 
parm1_426), with no appreciable decline in litter size throughout gestation, at 
birth, or at weaning. In contrast, SvEv-Ramp2+/- intercrosses (black solid line, 
Fig.3.1.A) showed a gradual and continuous decrease in litter size from 
implantation to weaning. 
Morphological evaluation of embryos from SvEv-Ramp2+/- intercrosses 
revealed a high incidence of fetal growth restriction compared with embryos from 
wild type SvEv crosses. Fig.3.1.B shows representative images of litters from 
E9.5 wild-type SvEV and SvEv-Ramp2+/- intercrosses. Although we noticed 
occasional fetal growth restriction in wild-type SvEV crosses, SvEv-Ramp2+/- 
intercrosses exhibited a high proportion of severe fetal growth restriction. In the 
representative example shown, three of eight embryos are severely growth 
restricted (marked by arrows). Moreover, the fetal growth restriction was 
independent of the genotype of the embryo, because two of the three growth-
restricted embryos were wild type. Consistent with these morphological 
observations, crown to rump length of E9.5 embryos from SvEv-Ramp2+/- 
intercrosses was significantly reduced compared with that of embryos from wild-
type SvEv intercrosses (Fig.3.1.C). Therefore, the dramatic and progressive 
decline in litter size in SvEv-Ramp2+/- intercrosses is not solely due to the 
embryonic lethality of Ramp2-/- embryos but is also caused by a high incidence of 
fetal growth restriction that affects both wild-type and Ramp2+/- embryos.  
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Genetic reduction of maternal Ramp2 causes postnatal pup and litter 
lethality 
In addition to fetal loss during gestation, a large percentage of individual 
pups, as well as entire litters, born to SvEv-Ramp2+/- females died within 1–2 d 
after birth. Within the 140 born litters we characterized from SvEv-Ramp2+/- 
intercrosses, we observed a 12% postnatal lethality of individual pups, double 
that of the 6% postnatal lethality rate observed for SvEV wild-type crosses 
(Fig.3.1.A). Most striking was our observation that nearly one quarter, 24%, of 
litters born to Ramp2+/- females lost all of the pups (12 complete litters died 
among the 50 litters examined). This unusually high rate of postnatal litter loss 
was not observed in wild-type SvEv mice maintained in our colony (one litter died 
among 30 litters examined, 3.3%) or in heterozygote intercrosses of Calcrl+/- or 
Adm+/- mice that are maintained on an identical isogenic 129SvEv/S6 
background in our colony. Moreover, our observations of average litter size at 
birth, at weaning, and percentage of entire litter loss from wild-type SvEv 
intercrosses are similar to the breeding characteristics established by Taconic 
Farmsaforathea129S6/SvEvTacastraina(www.taconic.com/wmspage.cfm?parm1
_426). Therefore, compared with control wild type SvEV intercrosses, these data 
reveal an unusually high incidence of postnatal lethality for individual pups, as 
well as entire litters, born to SvEv-Ramp2+/- intercrosses. 
 To determine whether this postnatal lethality was associated with the 
genotype or gender of the offspring, we tabulated the genotype and sex of both 
the surviving and dead pups from the 140 litters generated from SvEv-Ramp2+/- 
intercrosses. As shown in Fig.3.1.D (left pie charts), the genotypes of pups, both 
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surviving and dead, fit the expected Mendelian ratio of 1:2 (or 33:66%) for SvEv-
Ramp2+/+ and SvEv-Ramp2+/-, respectively, and do not show any association 
with lethality. Dead pups in which the quality of genomic DNA was not suitable 
for genotyping by PCR were not included in our analysis. Furthermore, we found 
no correlation between the sex of the pups and their lethality (Fig.3.1.D, right pie 
charts). These data reveal an unusually high incidence of postnatal pup lethality 
in SvEv-Ramp2+/- intercrosses that is independent of the genotype or gender of 
the offspring, suggesting that female Ramp2+/- mice have either abnormal rearing 
behavior and/or problems with lactation. Consistent with this hypothesis, we 
noticed that most of the postnatal dead pups had no milk in their stomachs. 
 To eliminate the confounding effects of Ramp2-/- embryos generated from 
heterozygote intercrosses and to determine whether the pup loss was dependent 
on the gender of either parent, we established and analyzed genetic reciprocal 
crosses in which only one parent was heterozygote for the Ramp2 gene. As 
shown in the black bars of Fig.3.1E, fetal loss throughout pregnancy and small 
litter sizes at birth were evident only when the dam was heterozygote for Ramp2. 
In contrast, litter sizes throughout pregnancy and at birth were not significantly 
affected when the male parent was heterozygote for Ramp2 (gray bars, 
Fig.3.1.E). Thus, genetic reduction of maternal Ramp2, but not of paternal 
Ramp2, causes fetal loss throughout pregnancy. Taken together, these data 
demonstrate that a modest genetic reduction in the maternal Ramp2 gene 
causes remarkable fetal growth restriction and fetal loss throughout pregnancy 
that is independent of fetal genotype. 
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Ramp2+/- female mice exhibit hyperprolactinemia and anterior pituitary 
gland hyperplasia 
 The absence of milk in the stomachs of postnatal dead pups born to SvEv-
Ramp2-/- female mice prompted us to measure serum prolactin in female mice 
during late gestation when mammary glands prepare for lactation (60). As 
expected, serum prolactin gradually increased with advancing gestation (from 
E14.5 to E18.5) in SvEv-Ramp2+/+ females bred to SvEv-Ramp2+/+ males 
(Fig.3.2.A), with an average level of 3.8 ng/ml. However, SvEv-Ramp2+/- females 
bred with SvEv-Ramp2+/- males had a significantly more robust increase in serum 
prolactin, averaging 20.5 ng/ml from E14.5 to E18.5, compared with controls (P < 
0.01, Fig. 3.2A). Moreover, Fig.3.2.B shows that basal levels of serum prolactin 
were 2-fold higher in nonpregnant SvEv-Ramp2+/- females compared with 
nonpregnant wild-type females, although this trend failed to reach statistical 
significance (11.7 ± 3.0 ng/ml SvEv-Ramp2+/+ vs. 25.8 ± 6.3 ng/ml SvEv-
Ramp2+/-; P = 0.06). The expression of prolactin mRNA was also significantly 
elevated 1.4-fold in the pituitary glands of 6-month old, virgin SvEv-Ramp2+/- 
female mice compared with SvEv-Ramp2+/+ female mice (Fig.3.2.C). 
 Immunohistochemistry on pituitary gland sections of 18-wk-old, virgin 
SvEv-Ramp2+/+ and SvEv-Ramp2+/- female mice confirmed the basal 
hyperprolactinemia phenotype. As shown in Fig.3.2.D, the lactotropes of the 
anterior pituitary gland of SvEv-Ramp2+/- female mice showed intense staining 
with an anti-prolactin antibody compared with moderate staining intensity in wild-
type control pituitaries. GH expression appeared somewhat elevated in the SvEv-
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Ramp2+/- mice compared with controls, a finding that may not be unexpected 
because lactotropes and somatotropes share a common lineage pre-cursor 
during embryogenesis. Therefore, we also evaluated relative levels of pituitary 
GH by quantitative real time PCR (SvEv-Ramp2+/+ = 1.04 ± 0.14, n = 9, vs. SvEv-
Ramp2+/- = 0.76 ± 0.07, n = 8) and serum levels of GH by RIA (SvEv-Ramp2+/+ = 
3.49 ng/ml ± 0.69, n = 10, vs. SvEv-Ramp2-/- = 3.98 ng/ml ± 0.33, n = 8) and 
found no significant differences between genotypes. In addition, Fig.3.2.D shows 
that there were no remarkable differences in staining intensity for any of the other 
hormone-producing cell types of the anterior pituitary (anti-TSH, -ACTH, -LH, and 
-FSH).  
 Because increased prolactin gene expression, synthesis, and secretion 
are often associated with lactotrope hyperplasia, we evaluated the size of the 
pituitary glands from 18-wk-old, virgin SvEv-Ramp2+/+ and SvEv-Ramp2+/- female 
mice. As shown in Fig.3.2.E, the pituitary gland of SvEv-Ramp2+/- mice appeared 
larger and was appreciably more dense and firm upon dissection compared with 
pituitaries from SvEv-Ramp2+/+ mice. Consistent with these morphological 
observations, SvEv-Ramp2+/- female mice had significant increases in pituitary 
gland volume and cell density compared with the pituitaries of wild type females 
(Fig. 3.2, F and G, respectively). The increase in pituitary cell density in SvEv-
Ramp2+/- mice was also readily appreciated in 4’,6-diamidino-2-phenylindole-
stained sections of pituitaries, shown in Fig. 3.2.D. Taken together, these results 
demonstrate that genetic reduction of Ramp2 in female mice leads to mild 
hyperprolactinemia, both basally and during pregnancy, which is associated with 
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enlarged and hyperplastic pituitary glands producing increased levels of 
prolactin. In this regard, when we used the Fisher method (61) to test for the 
combined significance of these related but independent variables, we found a 
highly significant (P < 0.0001) overall difference in prolactin measures between 
SvEv-Ramp2+/- mice and controls. 
Accelerated mammary gland development in Ramp2+/- mice  
 To determine whether the mild hyperprolactinemia of SvEv-Ramp2+/- 
female mice might contribute to abnormalities in mammary gland development 
and ultimately lactation defects, we performed whole-mount analyses of 
mammary glands from 18-wk-old, virgin SvEv-Ramp2+/+ and SvEv-Ramp2+/- 
female mice. We chose to evaluate mammary gland development of virgin mice 
rather than pregnant or lactating mice because variable litter sizes and suckling 
stimulus are known to influence mammary gland development and would 
confound the results for SvEv-Ramp2+/- mice. As shown in Fig.3.3.A, SvEv-
Ramp2+/- mice had accelerated branching of secondary and tertiary ducts (low 
magnification) as well as remarkably increased number of terminal end buds 
(high magnification) compared with SvEv-Ramp2+/+ female mice. Quantitation of 
mammary gland ductal branch points as well as terminal end buds showed a 
marked and significant increase in SvEv-Ramp2+/- mice compared with control 
animals (Fig.3.3, B and C, respectively). This precocious mammary gland 
development in SvEv-Ramp2+/- females was further supported by an increase in 
prolactin gene expression in the mammary glands (data not shown). 
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Ramp2+/- mice have delayed mineralization during development and 
decreased bone mineral content and density 
 To determine whether the mild hyperprolactinemia of SvEv-Ramp2+/- mice 
contributed to other endocrine phenotypes, we evaluated the bones of SvEv-
Ramp2+/- mice. Dual-energy x-ray absorptiometry (DEXA) analysis of excised 
femurs of 18-wk-old, virgin female mice revealed significantly reduced bone 
mineral content and bone mineral density in SvEv-Ramp2+/- mice compared with 
wild-type controls (Fig.3.4, A and B). Total bone area did not change significantly 
between the two groups of mice (Fig.3.4.C). Radiographic images of tibiae and 
femurs of SvEv-Ramp2+/- mice showed significantly longer bones compared with 
their wild-type controls (Fig.3.4, D and E). The tibiae of Ramp2+/- mice were 
significantly longer than wild-type controls (14.7 ± 0.3 mm for wild type and 15.89 
± 0.24 mm for SvEv-Ramp2+/-, P < 0.04), and the femurs generally appeared 
longer, although the difference did not reach statistical significance (11.9 ± 0.3 
mm for wild type and 12.5 ± 0.06 mm for SvEv-Ramp2+/-). Consistent with the 
DEXA analysis, microcomputed tomography (micro-CT) analysis of femurs from 
18-wk-old virgin mice showed that the reduced bone volume and density of 
SvEv-Ramp2+/- mice were associated with reduced cortical thickness and fewer, 
thinner trabecular structures compared with SvEv-Ramp2+/+ controls (Fig.3.4.F). 
The lumbar vertebrae of SvEv-Ramp2+/- mice were similar in length to SvEv-
Ramp2+/+ mice but appeared underdeveloped with wider growth plates, wider 
intervertebral discs, and reduced mineralization (Fig. 3.4.G). 
To distinguish whether these skeletal abnormalities were caused by the 
modest hyperprolactinemia or whether they arose independently of prolactin 
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dysregulation, we evaluated the hind limb bones and lumbar spines of SvEv-
Ramp2+/- pups 2 d postnatally. The femurs of the hind legs of SvEv-Ramp2+/- 
pups exhibited modest, yet statistically significant increases in bone volume 
compared with the wild-type pups, whereas the tibia volumes also trended to be 
greater in SvEv-Ramp2+/- pups (Fig.3.4.H). In the spine, there was also delayed 
development of the lumbar vertebrae as indicated by reduced mineralization of 
the epiphyseal plates of the vertebrae and delayed development of lumbar 
transverse processes (Fig.3.4.I).  
Despite these skeletal changes, SvEv-Ramp2+/- mice had no significant 
differences in circulating levels of calcium when compared with SvEv-Ramp2+/+ 
controls (SvEv-Ramp2+/- = 11.88 ± 0.96 mg/dl, and SvEv-Ramp2+/+ = 13.55 ± 
0.11mg/dl). Nevertheless, these results clearly demonstrate that 
haploinsufficiency for Ramp2 results in significant defects in bone homeostasis 
and development. 
Endocrine phenotypes of Ramp2+/- mice are strain dependent 
We have previously shown that the reduced fertility phenotype of Ramp2+/- 
mice was not present in Ramp2+/- intercrosses on an F2 129SvEv/S6-C57BL6 
genetic background (18). Consistent with this observation, we also found no 
significant increase in serum prolactin levels in nonpregnant F2-Ramp2+/- mice 
(data not shown). We also evaluated mammary gland development in F2-
Ramp2+/- females and found no significant differences compared with strain-
matched controls (data not shown). Therefore, the endocrine-related phenotypes 
of reduced fertility, postnatal pup loss, hyperprolactinemia, and accelerated 
 45 
 
mammary gland development in SvEv-Ramp2+/- mice can be rescued by 
crossing one generation onto a C57BL6 genetic background. These findings 
imply that the Ramp2 gene must have potent genetic modifiers that vary between 
common laboratory mouse strains. 
Discussion 
 We have previously shown that global knockout mice for either Ramp2, 
Calcrl (gene name for CLR), and Adm (gene name for AM peptide) share a 
strikingly similar phenotype of embryonic lethality associated with impaired 
lymphatic vascular development and interstitial edema (18, 43, 44). This striking 
similarity in phenotypes allowed us to conclude that the CLR/RAMP2/AM 
signaling complex is an essential mediator of lymphatic vascular development 
during embryogenesis. However, because the global knockouts die at 
midgestation, we have been limited in our ability to extend our phenotypic 
comparison of these mice to other phenotypes, particularly those that might be 
present in Ramp2+/- mice but not in Calcrl+/- or Adm+/- mice. 
 In this study, we have addressed this caveat by taking advantage of the 
viability of Ramp2+/- mice and characterized a constellation of endocrine-related 
phenotypes that include fetal loss throughout gestation, postnatal lethality of 
offspring, maternal hyperprolactinemia, accelerated mammary gland 
development, and altered skeletal properties and development. If these 
phenotypes were due solely to a reduction in signaling of the canonical CLR, 
then the logical expectation would be that female SvEv-Calcrl+/- mice should 
exhibit the same, or possibly exacerbated, phenotypes. However, SvEv-Calcrl+/- 
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mice (which we generated and maintained on the identical genetic background 
as SvEv-Ramp2+/- mice) do not exhibit postnatal pup lethality, do not have 
elevated serum prolactin, do not have hyperplastic pituitaries, and do not have 
accelerated mammary gland development (data not shown). Therefore, this 
divergence in phenotypes allows us to conclude that in adults, RAMP2 must 
have physiologically relevant functions that extend beyond its well-established 
role as a modulator of CLR function. This conclusion is entirely consistent with in 
vitro biochemical and pharmacological studies that show associations between 
RAMP2 and several other GPCRs involved in endocrine physiology, like PTHR1, 
CTR, and GCGR (Fig.3.5).  
 Determining exactly which receptors, or more likely which combination of 
receptors, ultimately underlies the endocrine phenotypes of SvEv-Ramp2+/- mice 
remains a challenging task. Once again, a comparison of phenotypes from 
genetic mouse models of RAMP2-interacting GPCRs and their ligands may 
provide the best clues. For example, PTHrP, via the receptor PTHR1, plays 
essential roles in fetal and placental development (62-63) and mammary gland 
development (64-65) and in the endochondral ossification process of bone 
development (66-69). Glucagon signaling through GCGR also plays a critical role 
in fertility and fetal development because Gcgr-/- female mice exhibit reduced 
fertility with embryonic death and perinatal lethality (70). Mice deficient for amylin, 
a peptide ligand for the calcitonin-RAMP2 receptor complex, display bone 
phenotypes similar to Ramp2+/- mice (83). Last but not least, AM, the ligand for 
the canonical CLR-RAMP2 complex, can induce osteoblast proliferation in vitro 
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and increase bone formation in vivo (71) and is fundamentally required for 
normal female reproduction. And so, considered all together, it is most likely that 
the endocrine phenotypes of Ramp2-heterozygote mice are the combined result 
of reduced signaling for a cohort of previously identified, and yet to be identified, 
RAMP2-interacting GPCRs (Fig.3.5).  
Additional genetic lines in which the compound haploinsufficient loss of 
RAMP2 with either CLR or other RAMP2-associating GPCRs could potentially 
shed light on which endocrine organ system is predominantly affected by a 50% 
reduction in RAMP2. For example, a compound RAMP2/CLR heterozygote 
mouse may show predominant phenotypes in the female reproductive system, 
whereas a compound RAMP2/PTHR1 heterozygote mouse may exhibit 
predominant phenotypes in the skeletal system.  
 Another important aspect of these findings, which further implies the 
involvement of multiple RAMP2-interacting GPCRs, is that the SvEv-Ramp2+/- 
phenotype is manifested on a haploinsufficient background. Although robust 
endocrine phenotypes are revealed in global knockouts and transgenic 
overexpression mouse models for many individual RAMP2-interacting GPCR and 
their ligands, it is remarkable that a modest 50% reduction in RAMP2 can result 
in similarly robust phenotypes. This constellation of phenotypes is also likely to 
be influenced by the very broad spatiotemporal expression pattern of RAMP2 
compared with individual GPCR. Therefore, these results demonstrate that the 
appropriate genetic dosage of Ramp2 is required for normal female reproduction 
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and endocrine homeostasis and that this requirement is likely to involve 
numerous GPCR. 
 In summary, we have demonstrated that a modest genetic reduction in the 
GPCR accessory protein Ramp2 causes severe female subfertility, mild 
hyperprolactinemia, and endocrine-related defects in mammary gland and bone 
target organs. Although we cannot solely attribute these phenotypes to 
hyperprolactinemia, the presence of bone phenotypes as early as postnatal d 2 
argues for a direct role of RAMP2 in bone development that is independent of 
hyperprolactinemia. In a broader context, the constellation of endocrine 
phenotypes demonstrates that RAMP2 has physiological functions that extend 
well beyond its interaction with the canonical CLR. The elucidation of the specific 
receptors (or combination of receptors) that underlie the Ramp2+/- phenotype in 
different tissues will ultimately require more sophisticated mouse modeling 
approaches. However, these phenotypic data provide a valuable research 
resource from which to begin exploring novel pharmacological and biochemical 
GPCR-RAMP2 interactions. Given the pharmacological tractability of GPCR-
RAMP2 interfaces, these and future studies have the potential to identify receptor 
targets for the therapeutic treatment of numerous endocrine-related conditions 
such as infertility, osteoporosis, and hyperprolactinemia. 
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Figure 3.1 Reduced fertility in SvEv-Ramp2+/- females and high incidence of 
postnatal lethality in SvEv-Ramp2+/- litters.  
A, Average number of pups per litter after implantation to weaning (SvEv-
Ramp2+/+ intercrosses R2 value = 0.74; SvEv-Ramp2+/- intercrosses R2 value = 
0.97). A total of 140 litters were scored for SvEv-Ramp2+/- intercrosses at birth 
and weaning, and 55 litters were scored for SvEv-Ramp2+/+ intercrosses. Unless 
otherwise mentioned, three to 17 litters per gestational time point were scored. 
The black arrows indicate the gestational age at which Ramp2-/- embryos die 
from lymphatic vascular defects and at which postnatal pup loss is observed in 
SvEv-Ramp2+/- intercrosses. B, Representative litters from wild-type SvEv and 
SvEv-Ramp2+/- intercrosses at E9.5 of pregnancy, showing a high incidence of 
fetal growth restriction that is independent of fetuses’ genotype in SvEv-Ramp2+/- 
intercrosses. Arrows point to severely growth-restricted embryos. Embryos were 
imaged at the same magnification and later grouped digitally based on their 
genotype. C, Crown to rump length (millimeters) of E9.5 embryos from SvEv-
Ramp2+/+ intercrosses and SvEv-Ramp2+/- intercrosses; *, P < 0.05. Number in 
the column represents number of embryos measured. D, Pie charts 
demonstrating that postnatal death observed from 140 SvEv-Ramp2+/- intercross 
litters was independent of pup genotype (left) and pup gender (right). Note that 
the white slice of the lower left pie chart represents a single Ramp2-/- mouse that 
we discovered alive after birth. Consistent with the knockout phenotype, this 
animal was severely hydropic. E, Reciprocal crosses of SvEv-Ramp2+/- mice. An 
average of two to three litters were scored for each time point. Loss of pups 
throughout pregnancy was observed only when the female was SvEv-Ramp2+/-. 
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Figure 3.1 
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Figure 3.2 SvEv-Ramp2+/- females exhibit hyperprolactinemia and hyperplastic 
pituitary glands.  
A, Maternal serum prolactin levels in wild-type SvEv-Ramp2+/+ and SvEv-
Ramp2+/- intercrosses on E14.5, E16.5, and E18.5 of gestation. *, P < 0.01, by 
one-way ANOVA; n ≥ 5 mice per group and time point. B, Basal serum prolactin 
levels in nonpregnant mice; n = 25 for wild-type SvEv-Ramp2+/- females, and n = 
14 for SvEv-Ramp2+/+ females. P = 0.06. C, Quantitative RT-PCR of prolactin 
gene expression, normalized to GAPDH expression, in the anterior pituitary 
glands of 6-month-old, virgin SvEv-Ramp2+/- female mice (black bars) compared 
with the wild-type SvEv-Ramp2+/+ controls (gray bars); n = 8 mice per genotype. 
*, P < 0.05. D, Immunohistochemistry on cryosections of pituitary glands from 
virgin wild-type and SvEv-Ramp2+/- female mice using antibodies against six 
anterior pituitary hormones: ACTH, prolactin (PRL), GH, TSH, FSH, and LH. 
Images are representative of n = 8 pituitaries analyzed for each   genotype. E, 
Images of dissected pituitary glands from wild-type and SvEv-Ramp2+/- females, 
showing enlarged pituitary glands in SvEv-Ramp2+/- mice. F, Volume of the 
pituitary gland is significantly larger in SvEv-Ramp2+/- female mice (black bars) 
compared with the controls (gray bars). *, P < 0.03. Scale bar, 500 µm. G, Cell 
density of anterior pituitary gland is significantly increased in SvEv-Ramp2+/- 
female mice (black bars) compared with the controls (gray bars). *, P < 0.01. 
Mice were 18-wk-old virgin females at time of euthanasia; n ≥ 5 mice per 
genotype. 
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Figure 3.2 
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Figure 3.3 Accelerated mammary gland development in SvEv-Ramp2+/- female 
mice.  
A, Fourth inguinal mammary glands of 18-wk-old SvEv-Ramp2+/- and wild-type 
virgin female mice were dissected, fixed in Carnoy’s fixative, and stained with 
Carmine dye. Lymph nodes were used as a reference point; n = 15–20 mice per 
genotype. Scale bars, 1 mm (low magnification) and 100 µm (high magnification). 
B, Quantitation of ductal branch points within two independent 30-mm2 areas per 
sample/animal. *, P < 0.01; n = 9 for SvEv-Ramp2+/+, and n = 6 for SvEv-
Ramp2+/- C, Quantitation of terminal end buds (TEBs) along a 5-mm peripheral 
duct. *, P <0.05; n = 9 for SvEv-Ramp2+/+, and n = 6 for SvEv-Ramp2+/-. 
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Figure 3.4 Ramp2+/- mice have skeletal abnormalities.  
A–C, DEXA analyses of femurs showing decreased bone mineral content in 
milligrams (A), decreased bone mineral density in milligrams per square 
centimeters (B) (*, P < 0.01) and C) unchanged bone area in square centimeters 
(C); D, radiographs of tibiae; E, radiographs of femurs; F, micro-CT of midregion 
of femurs; G, 3D model of lumbar vertebrae; H, tibial and femoral bone volume 
(*, P < 0.05); I, skeletal staining by Alcian blue; Alizarin red (unmineralized bone 
and cartilage in blue, mineralized bone in purple). Animals used for the 
experiments in A–G are 18-wk-old virgin female SvEv-Ramp2+/+ and SvEv-
Ramp2+/- mice; n = 8–10 per genotype for DEXA, and n = 3 for micro-CT analysis 
and radiographs. Animals used in H and I are 2-d-old pups of SvEv-Ramp2+/+ (n 
= 5) and SvEv-Ramp2+/- genotypes (n = 3). 
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Figure 3.5 Proposed model for phenotypic outcomes in Ramp2+/- mice. 
The constellation of phenotypes observed in SvEv-Ramp2+/- mice is likely due to 
a combined effect of reduced signaling for many GPCR and ligands and perhaps 
others that have yet to be identified. 
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CHAPTER 4 
 
A ROLE FOR RECEPTOR ACTIVITY MODIFYING PROTEIN-2 (RAMP2) AND 
PARATHYROID HORMONE RECEPTOR 1 (PTHR1) IN PLACENTAL 
DEVELOPMENT 
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ABSTRACT 
 Receptor activity-modifying protein-2 (RAMP2) is a single-pass 
transmembrane protein that regulates the trafficking, ligand binding and signaling 
of several G protein-coupled receptors (GPCRs). In vitro, RAMP2 has been 
shown to interact with several GPCRs, including calcitonin receptor-like receptor 
(CLR), parathyroid hormone receptor (PTHR1), calcitonin receptor (CTR) and 
glucagon receptor (GCGR). The most well-characterized role of RAMP2 is in the 
regulation of adrenomedullin (AM) binding to calcitonin receptor-like receptor 
(CLR) and our previous in vivo studies using knockout mouse models support 
this canonical signaling paradigm.  However, we have also demonstrated 
previously that Ramp2+/- mice exhibit a constellation of endocrine-related 
phenotypes which are distinct from those of Adm+/- and Calcrl+/- mice, 
demonstrating that RAMP2 has physiological functions beyond AM/CLR 
signaling.  Here, we characterize Ramp2-/- placentas, and show a variety of 
phenotypes distinct from those of Adm-/- and Calcrl-/- placentas, further supporting 
an extended function of RAMP2 with other GPCRs. In situ hybridization of 
Ramp2 in wild type placentas revealed robust expression in the fetal labyrinth 
layer. Consistent with this expression pattern, Ramp2-/- placentas had a thinner 
labyrinth layer with significantly fewer trophoblast cells and reduced proliferation 
compared to littermate Ramp2+/- placentas. Interestingly, this phenotype is not 
observed in Adm-/- and Calcrl-/- placentas, suggesting that other RAMP2-
associated GPCRs may be involved. Because PTHR1 plays a role in proliferation 
of trophoblast cells, we hypothesized that the cause of placental phenotypes in 
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Ramp2-/- mice could be partially due to compromised PTHR1 signaling. Using 
placental extracts from Ramp2-/- and control mice, we discovered that the gene 
and protein expression of PTHR1 was reduced in Ramp2-/- placentas compared 
to controls. This work is the first in vivo evidence demonstrating an essential role 
for RAMP2 in placental development related to PTHR1 expression and function.  
Introduction  
 The placenta forms the maternal-fetal interface, a site for nutrient supply, 
exchange of gases and waste uptake and is a critical organ for the successful 
outcome of pregnancy. A mature mouse placenta consists of three major layers: 
a maternal layer which attaches to the uterus, a junctional zone that connects the 
maternal part of the placenta to the fetus, and finally the fetal compartment, 
called the labyrinth (72).  The labyrinth contains highly branched villi that are 
composed of trophoblast cells, stromal cells and blood vessels, and it is the site 
of nutrient exchange.  The junctional zone is composed of spongiotrophoblast 
cells that form a supporting structure lining the labyrinth and the giant trophoblast 
cells dividing the maternal and the fetal compartments. The maternal side of the 
placenta, also referred to as the decidua, contains the maternal vasculature 
through which maternal blood enters the placenta. At mid gestation, spiral 
arteries of the decidua transform into low-resistance and high capacitance 
vessels to meet the increasing demands of the growing embryo. A balanced 
cross-talk between multiple proteins and different cell types is required for a 
successful pregnancy. Therefore, any perturbation in this balance can result in 
complications of pregnancy, such as ectopic pregnancy, intrauterine growth 
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restriction, preterm birth and preeclampsia. Although several studies using 
genetically engineered mouse models have provided much insight into the 
intricate communication that occurs at the maternal-fetal interface and have 
revealed key molecular players involved in placental development (73), there is 
still plenty to be understood.  
      Receptor activity modifying proteins (RAMP) are type1 membrane proteins 
that pass the membrane once. There are three mammalian RAMPs encoded by 
three different genes. RAMPs function to modify G-protein coupled receptor 
signaling in several ways: i) altering GPCR trafficking to and from the cell surface 
(1) or from recycling endosomes (6-7), ii) altering GPCR pharmacology by 
dictating ligand-binding specificity (1), and iii) influencing signaling downstream of 
GPCRs (3). Calcitonin receptor-like receptor (CLR), the first identified receptor 
partner for RAMPs, requires RAMPs for it to be trafficked to the plasma 
membrane. Depending on the RAMP expressed, CLR binds to different ligands. 
For example, CLR bound to RAMP1 forms a receptor for the neuropeptide, 
calcitonin gene related peptide (CGRP), while CLR bound to RAMP2 or RAMP3 
forms adrenomedullin receptor 1 and adrenomedullin receptor 2 for the peptide 
hormone Adrenomedullin, respectively. Studies show that RAMPs associate with 
7 other GPCRs: Calcitonin receptor (CTR), parathyroid hormone receptor 1 and 
2 (PTHR1, PTH2R), type 1 receptor for vasoactive instestinal peptide (VPAC1), 
glucagon receptor (GCGR), secretin receptor (SCTR) and calcium sensing 
receptor (CaSR) (2-5); but their expression data (57) suggests a broader role 
than hitherto known. Since most studies identifying novel RAMP-interacting 
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GPCR receptor partners have not addressed the physiological significance of the 
GPCR-RAMP interaction, there is a greater need for investigating the functions of 
these interactions in normal and pathological conditions. Importantly, based on 
the wide expression of RAMPs and their drug tractable properties, RAMPs carry 
therapeutic potential for several disease conditions such as migraine, 
cardiovascular disease, diabetes, osteoporosis, inflammation, and female fertility 
(18-19, 22, 25, 42, 74). 
       In recent years, genetic mouse models of RAMPs have provided great 
insight on the broad roles of RAMP proteins. A comprehensive review of the 
various mouse models of RAMPs is described elsewhere (24). Briefly, loss of 
RAMP2 leads to embryonic lethality (17, 23). More recently, we have shown that 
haploinsufficiency of Ramp2 disrupts endocrine homeostasis leading to problems 
such as subfertility and weakened skeletal system in female mice (25).  Although 
RAMP1 and RAMP3 are not essential for survival, mice lacking Ramp1 exhibit 
mild phenotypes involving cardiovascular and inflammatory processes (42), while 
Ramp3-/- mice exhibit a lean phenotype in their old-age (17).  
       In this study, we utilized Ramp2-/- mice to evaluate the role of RAMP2 in 
placental development. Additionally, we hypothesized that RAMP2 regulates 
PTHR1 function in the placenta and tested the physiological importance of 
PTHR1-RAMP2 association. Our findings demonstrate an essential role for 
RAMP2 in placental development. RAMP2 is required for proliferation of 
trophoblast cells and for the successful remodeling of spiral arteries. Surprisingly, 
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loss of RAMP2 compromises PTHR1 expression levels, suggesting an additional, 
unique layer of regulation of GPCR signaling by a RAMP.  
Materials and Methods  
Animals: Ramp2 null mice were generated and characterized as described 
previously (17). Genotyping was performed as recently described in the article 
that characterizes haploinsufficiency of Ramp2 in the female endocrine system 
(25). Although the Ramp2 knockout phenotype is conserved in SvEV129/6-TC1 
mice and in C57Bl6 mice, the current study involves the characterization of 
Ramp2 null placentas generated on SvEV129/6-TC1 background.  To obtain 
timed-pregnancies, mice were allowed to mate and the morning of vaginal plug 
detection was considered to be embryonic day 0.5 (E0.5d). Placentas from 
littermate controls were used in all studies. Amniotic fluid was collected from 
E13.5 to E14 days embryos by placing the embryo with its yolksac intact in an 
eppendorf tube and then gently piercing the yolk sac with a fine needle. This 
allowed the amniotic fluid to drain into the collection tube. Samples were snap 
frozen on dry ice and stored at -80C until assayed. Calcium measurements were 
performed as previously described (25). All experiments performed on animals 
were approved by the Institutional Animal Care and Use Committee of The 
University of North Carolina at Chapel Hill.  
Histology, immunohistochemistry and microscopy: The antibodies used in 
this study are anti-cytokeratin (Dako), anti-BrdU (Zymed), anti-Ki-67 (Dako), anti 
α-smooth muscle actin (Sigma). All tissues were fixed in 4% paraformaldehyde 
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overnight, cryoprotected in 30% sucrose overnight, embedded in OCT (Tissue-
Tek) and serially sectioned at 8-10µm.  Sections were rehydrated in PBS, 
permeablized in 0.2% Triton-X100, blocked in 4%BSA and incubated in primary 
antibody overnight. After washing, sections were incubated in appropriate 
secondary antibody for 1-2hours, washed and mounted for imaging. Images were 
acquired on a Nikon E800 microscope with a Hammamatsu ORCA-ER charge-
coupled device camera with Metamorph software (Molecular Devices Corp.) and 
processed with Photoshop.  
In situ hybridization: Placentas from embryonic day 14.5 from wildtype 
129S6/SvEv intercrosses were collected and processed same as the tissue for 
immunohistochemistry except that the PFA and sucrose solutions were prepared 
in diethylypyrocarbonate treated phosphate buffered saline. Placentas were 
serially sectioned at 16µm thickness. Non-radioactive in situ hybridization was 
performed as previously described (53) using sense and antisense RNA probes 
synthesized from plasmids containing cDNA sequences of mouse Ramp2.   
RNA extraction, cDNA synthesis and Quantitative RT-PCR analyses:  RNA 
was extracted using the Trizol method following the manufacturer’s protocol 
(Ambion, Austin, Texas).  Isolated RNA was DNase treated and reverse 
transcribed using the M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, 
California) and gene expression was measured by MX3000 Q-PCR machine 
from Stratagene, Santa Clara, California. TaqMan probes purchased from 
Applied Biosystems (Carlsbad, California) were used to measure the gene 
expression of Pth1r, catalog # Mm00441046_m1.  For the rest of the genes 
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tested, SYBR green master mix purchased from Sigma (St. Louis, Missouri), 
catalog# 4438, was used. Primer sequences were obtained from previously 
published references for the following genes: plasma membrane Ca2+ ATPase 1 
(PMCA1), Mm_PMCA1_F(CGCCATCTTCTGCACCATT), Mm_PMCA1_R (CAG 
CCATTGCTCTATTGAAAGTTC) (75); transient receptor potential vanilloid 5 
channel (TRPV5), Mm_TRPV5_F(ATTGACGGACCTGCCAATTACAGAG), 
Mm_TRPV5_R(GTGTTCAACCCGTAAGAACCAACGGTC) (76); transient 
receptor potential vanilloid 6 channel (TRPV6), TRPV6_F 
(ATCGATGGCCCTGCGAACT), TRPV6_R(CAGAGTAGAGGCCATCTTG 
TTGCTG) (76); Calbindin-D9k, Calb-D9K_F(TCCTGCAGAAATGAAGAGC A), 
Calb-9K_R(GTGCTGTTGAACTCCTTCT) (76); Calbindin D28k Calb-
D28K_F(AACTGACAGAGATGGCCAGGTTA),  Calb-D28K_R    (TGAACTCTTT 
CCCACACATTTTGAT) (77); vitamin D receptor (VDR), 
VDR_F(AACGCTATGACCTGTGAAGGC), Mm_VDR_R(CCTGTACTTACG 
TCTGCACGA) (78); 1α-hydroxylase, 1AH_F(CCAGAGCGCTGTAGTT 
TCTCATCA), 1AH_R(ATGAAGGTTTCTGTGTCAGGAGGG) (79); and Na-Ca 
exchanger, NCX1_F(TCCCTACAAAACTATTGAAGGCACA), NCX1_R (TTT 
CTCATACTCCTCGTCATCGATT) (75). mGAPDH (25) was used as a 
normalizing gene and ∆∆CT method was used to analyze the relative levels of 
gene expression (80).  
SDS-page and western blotting: Placental extracts were quantified by BCA 
assay to determine the protein concentration. Samples were lysed in sample 
buffer, boiled for 5 minutes at 100 degrees centigrade and then loaded onto a 4-
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12% polyacrylamide gel and resolved by SDS-PAGE. Protein was then 
transferred to a nitrocellulose membrane which was subsequently blocked in 5% 
non-fat dry milk overnight at 4 degrees. The membranes were incubated with the 
primary antibodies (PTHR1 at 1:100 dilution; from Covance, Princeton, NJ and 
GAPDH at 1:1000 dilution from Sigma, Saint Louis, MO) overnight 4 degrees 
centigrade and detected with secondary antibodies as described previously (18). 
The blot was imaged with the Odyssey infrared scanner and data was obtained 
using scanner software. 
Statistical Analysis: All quantitative analyses were performed using unpaired, 
two-tailed Student’s t-test. Data are represented as standard error of mean 
(SEM) unless indicated otherwise. Differences were considered significant when 
the p value was lower than 0.05. 
Results  
Ramp2 is robustly expressed in the labyrinth layer 
 To assess the localization and extent of expression of Ramp2 in the 
mouse placenta, we performed in situ hybridization on E14.0 wild type placentas. 
As shown in Fig.4.1A, there was a robust expression of Ramp2 in the fetal 
compartments compared to diffused and weak signal in the maternal decidual 
regions of the placenta. More specifically, Ramp2 expression noticed was 
evident in the chorionic plate, labyrinth, spongiotrophoblast cells and in the giant 
trophoblast cells, with robust expression in the trophoblast cells of the labyrinth 
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layer (Fig.4.1B). These results suggest a critical role for RAMP2 in the fetal 
compartment of the placenta and specifically in the labyrinth.   
Ramp2-/- placentas exhibit abnormal development of the labyrinth layer 
 To investigate the consequence of the loss of RAMP2 in placental 
development, we performed histological analyses of placental sections obtained 
from timed-pregnancies of Ramp2+/- intercrosses. Hemotoxylin and eosin staining 
of E13.5 placentas revealed the presence of all the layers of the placenta (Fig. 
4.2A & B). However, the labyrinth layer of the Ramp2-/- placenta had distinctly 
less cellularity, as evidenced by the relative reduction of eosin staining  
compared to Ramp2+/+ placentas. Morphometric evaluation of stained sections 
showed no change in the labyrinth width, but a significant decrease in the 
thickness of Ramp2-/- labyrinth layer compared to that of littermate controls (Fig. 
4.2.C & D).   
Numerous mutant mouse models have been described with a “small labyrinth”, in 
which the phenotype is manifested by a reduction in labyrinth trophoblast cell 
number, often leading to fetal growth restriction or death of the fetus due to 
improper nutrient exchange (reviewed in (81)). We therefore hypothesized that 
the thin labyrinth layer in Ramp2-/- placentas could be caused by fewer 
trophoblast cells. To test this, we performed immunohistochemistry using an anti-
cytokeratin antibody that specifically marks trophoblast cells. We found a 
markedly reduced density of trophoblast cells in the Ramp2-/- placentas 
compared to their littermate controls (Fig.4.2E & F). We also quantified labyrinth 
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trophoblast cells from E14 day wild type and Ramp2-/- placentas, based on 
histological identification. As shown in Fig 4.2G, Ramp2-/- placentas indeed had 
fewer trophoblasts in the labyrinth region compared to the controls. These data 
indicate a role for RAMP2 in the regulation of trophoblast cell number and also in 
the proper formation of the labyrinth layer.  
Ramp2 plays a role in proliferation of trophoblast cells 
 To determine if the decreased thickness of the labyrinth and reduced 
numbers of trophoblast cells were due to a failure of trophoblast cells to 
proliferate at the normal rate, we performed BrdU incorporation studies in 
Ramp2+/- pregnant mice bred with RAMP2+/- males at day 14 of gestation. 
Immunohistochemistry with anti-BrdU antibody revealed a striking change in 
proliferation between wild type and knockout placentas. Particularly, the labyrinth 
layer of Ramp2-/- placentas had a marked reduction in signal compared to their 
controls (Fig.4.3A & B). Consistently, as shown in Fig.4.3C & D, Ki-67 staining 
also showed reduced signal in the labyrinth of Ramp2-/- placentas compared to 
the wild type littermate placentas. Taken together, these results demonstrate that 
RAMP2 plays an important role in proliferation of trophoblast cells of the labyrinth 
layer.  
Ramp2 does not influence apoptosis in the placenta 
 To eliminate the possibility of increased apoptosis as a factor contributing 
to the reduction in trophoblast cells, we performed QRT-PCR to determine the 
expression of pro-apoptotic Bax and anti-apoptotic Bcl2. The ratio of Bax to Bcl2 
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did not differ between the two genotypes (Fig.4.3E). Our results demonstrate that 
loss of RAMP2 in the developing placenta does not alter apoptosis.  
Loss of Ramp2 results in failed spiral artery remodeling 
 Remodeling of maternal spiral arteries into low resistance, high 
capacitance vessels is a critical process for maintaining appropriate placental 
function and promoting fetal health in both rodents and humans. A failure of 
spiral arteries to remodel is considered a hallmark pathophysiological feature of 
preeclampsia. Using a smooth muscle actin antibody, we stained decidual 
sections of wild type and Ramp2-/- placentas in order to evaluate the extent of 
vascular smooth muscle coverage surrounding the maternal spiral arteries. As 
expected, the spiral arteries of wild type placentas progressively lost their smooth 
muscle coverage as they approved the maternal-fetal interface. However, 
interestingly, there was a prominent amount of smooth muscle coverage left on 
the spiral arteries of Ramp2-/- placentas (Fig.4.4A&B). 
 More interestingly, the spiral artery phenotype of Ramp2-/- placentas 
phenocopies that of Adm-/- and Calcrl-/- placentas strongly suggests that AM 
signaling is involved in spiral artery remodeling. Uterine natural killer (uNK) cells 
have been implicated in spiral artery remodeling. Several studies suggest that 
factors released by uNK cells trigger spiral arteries to remodel (82-84). 
Consistent with a failure of spiral arteries to remodel, Adm-/- placentas and Calcrl-
/-
 placentas show a remarkable decrease in uNK cell number (Li M and Caron K 
et al, manuscript in preparation). Therefore, to determine if this phenotype was 
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conserved in Ramp2-/- placentas, we performed IHC of DBA lectin on E14.0 
Ramp2-/- and WT placentas generated from Ramp2+/- intercrosses.  Contrary to 
the phenotype observed in Adm-/- and Calcrl-/- placentas, Ramp2-/- placentas had 
no change in uNK cell number compared to WT littermate placentas (Fig.4.4C-
E).  
Taken together, our results show that RAMP2 is required for maternal 
spiral artery remodeling in a manner that is independent of uNK cell recruitment 
and likely distinct from canonical AM/CLR signaling. In addition, the marked 
labyrinth phenotype of Ramp2-/- placentas, which is not observed in Adm-/- and 
Calcrl-/- placentas, strongly indicates the involvement of one or more RAMP2-
interacting-receptor(s), besides CLR, in the normal development of the labyrinth 
layer.  
Influence of Ramp2 on the gene expression of RAMP2-interacting GPCRs 
To elucidate which putative GPCRs might be involved in the Ramp2-/- 
placenta phenotype, we performed QRT-PCR on numerous GPCRs that have 
previously been described to interact with RAMP2 (Fig.4.5). We found a robust 
and statistically significant increase in Calcrl gene expression, which is entirely 
consistent with a potential homeostatic up-regulation of AM signaling 
components in the absence of RAMP2 and with the presence of excessive 
vascular smooth muscle cells in Ramp2-/- placentas, which express high levels of 
Calcrl. We also observed a modest, yet significant, increase in glucagon 
receptor; however a function for this receptor in placental development has not 
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been previously appreciated. Most importantly, we found a dramatic 50% 
reduction in the expression of Pthr1, the receptor for PTH and PTHrP, which has 
numerous well-characterized roles in trophoblast proliferation and placental 
development (85-87). 
Loss of Ramp2 alters PTHR1  protein levels 
 To determine whether the reduced levels of Pthr1 mRNA correlated with 
reduced expression, we determined the levels of PTHR1 in Ramp2-/- knockout 
placentas using both western blotting and immunofluorescence. Consistent with 
the mRNA data, we found a reduction in protein levels in placental lysates by 
immunoblotting (Fig.4.6A). Immunohistochemistry for PTHR1 further showed that 
this receptor is highly expressed in the labyrinth layer and that Ramp2-/- 
placentas (Fig.4.6C&E) had considerably less staining compared to wild type 
placentas (Fig.4.6B&D). Our results provide compelling evidence that loss of 
RAMP2 alters Pthr1 gene and protein expression in the placenta. Moreover, this 
data suggests that the possible explanation for abnormal development of the 
labyrinth in Ramp2-/- mice is the loss of RAMP2 in the placenta compromising the 
function of PTHR1.  
Functional changes downstream of PTHR1 signaling 
Since PTHR1 signaling plays a critical role in maternal-fetal calcium 
transfer (86, 88-89), we measured amniotic fluid calcium content in E14.0 day 
Ramp2-/- yolk sacs and their control littermates; a day before Ramp2-/- embryos 
die due to lymphatic vascular defects.  As shown in Fig.4.6F, we noticed no 
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significant change in calcium content between the two genotypes. This finding 
was not unexpected since the window of active materno-fetal calcium transfer 
occurs from E16.5 to birth, such that the E14.5 lethality of Ramp2-/- embryos 
precluded our ability to address this. Nevertheless, we hypothesized that calcium 
handling genes, which are targets of PTHR1 signaling, would be expressed by 
E14.5 days of gestation. Therefore, we performed QRT-PCR on WT and Ramp2-
/-
 placentas to test the expression of plasma membrane Ca2+ ATPase 1 
(Pmca1), transient receptor potential vanilloid 5 channel (Trpv5), transient 
receptor potential vanilloid 6 channel (Trpv6), Calbindins- D9k and D28k, vitamin D 
receptor (Vdr), 1α-hydroxylase and Na-Ca exchanger.  Expression of Calbindin-
D9k, VDR and TRPV5 was below detectable levels in placentas of all genotypes. 
TRPV6 and Calbindin-D28k were expressed but showed no differences between 
wild type and Ramp2-/- placentas (data not shown). Interestingly, the plasma 
membrane Ca2+ ATPase 1, Pmca1 expression was significantly elevated in 
Ramp2-/- placentas compared to their littermate controls (Fig.4.6G). Taken 
together, our results suggest a compensatory mechanism as a consequence of 
compromised PTHR1 function, wherein the placenta up-regulates production of 
plasma membrane Ca2+ ATPase 1 channels in the absence of RAMP2 to 
maintain homeostasis of placental calcium transfer.   
Discussion 
 The role of RAMP2 in embryogenesis and in the adult female endocrine 
system has been previously determined (18, 25). However, the role of RAMP2 in 
placental development has not been understood. Therefore, the goal of this study 
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was to identify the role of RAMP2 in placentation.  In this study, we reported the 
first evidence that RAMP2, particularly of fetal origin, is essential for normal 
development of the placenta. Moreover, our study is the first to associate a 
critical role for a RAMP protein in placental formation. Consistent with the spatial 
localization of Ramp2, loss of Ramp2 led to a defective labyrinth. Ramp2-/- 
placentas generated from intercrosses of Ramp2+/- mice exhibited a 40% 
reduction in thickness of the labyrinth layer, compared to their WT littermate 
placentas.  This decrease in thickness is likely due to reduced trophoblast cell 
numbers in the labyrinth. Moreover, as evidenced by BrdU incorporation studies 
and Ki67 labeling, loss of RAMP2 significantly reduced the proliferation of these 
trophoblast cells. The absence of labyrinth abnormalities in placentas null for the 
canonical receptor partner of RAMP2- CLR, or the ligand AM, suggested to us 
that RAMP2 is associating with another receptor to mediate its role in the 
labyrinth layer.  
 Our studies provide evidence for a role for RAMP2 in preeclampsia. A 
hallmark sign of PE is a failure of the maternal arteries to shed their smooth 
muscle coverage to become low resistance vessels with increased capacitance 
(90). Although Ramp2+/- pregnant dams with Ramp2-/- embryos do not develop 
preeclampsia, our studies demonstrate that RAMP2 is involved in spiral artery 
remodeling, thereby having implications in the pathology of preeclampsia. The 
most conceivable explanation for the dams not developing PE is because the 
knockout embryos die embryonically, perhaps before the onset of PE. No change 
in uNK cell number suggests that there could be alternate mechanism(s) that 
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govern spiral artery remodeling. It is worth mentioning that this absence of uNK 
cell phenotype is not conserved in Adm-/- and Calcrl-/- mice, implying CLR-
independent roles for RAMP2 in spiral artery remodeling.  
Parathyroid hormone (PTH), its related peptide (PTHrP), and their 
common receptor PTHR1 are all shown to be expressed in the placenta. Elegant 
studies performed by Kovacs and colleagues demonstrate the role of PTH and 
PTHrP in maternal-fetal calcium transfer (86, 88)   PTHrP is produced by 
placental trophoblast cells (91) and has been shown to mediate trophoblast cell 
proliferation (87). Comparative study of Ramp2-/- mice and other mouse models 
of PTHR1 signaling prompted us to hypothesize that PTHR1 is interacting with 
RAMP2 to regulate trophoblast cell proliferation and placental calcium transfer. 
Our data revealed a decline in PTHR1 mRNA and protein levels in the placentas 
lacking RAMP2. This data is consistent with our hypothesis and further supports 
the biochemical studies (3) as well as our in vivo studies (25) that RAMP2 
associates not only with CLR, but with an additional GPCRs in vivo. Additionally, 
our data provides the first evidence that a RAMP protein can regulate GPCR 
mRNA and protein expression.  
Our data showing a change in gene expression of Plasma membrane 
calcium ATPase 1 suggests compensation to maintain homeostasis of maternal 
calcium transfer. While we do not notice a change in maternal fetal calcium 
transfer, as measured by amniotic fluid content, it is likely possible that PTHR1 
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function in calcium transfer across the placenta would be compromised in 
Ramp2-/- placentas if the embryos had survived beyond mid gestation.  
Taken together, this study elucidates the essential role of RAMP2 in 
placental development and demonstrates the involvement of RAMP2 in PTHR1 
regulation and function. Understanding how RAMP2 regulates PTHR1 gene and 
protein expression and the physiological outcome of PTHR1-RAMP2 interaction 
still remains complex. Future studies using in vitro approaches in trophoblast cell 
lines or different mouse models can elucidate the precise significance of this 
interaction. The previously established therapeutic role of PTH and PTHrP in 
various diseases like osteoporosis (92-93) and cancer (94-95) further emphasize 
the significance of understanding the physiological outcome of PTHR1-RAMP2 
interaction.  
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Figure 4.1 Expression of Ramp2 in the placenta  
In situ hybridization of Ramp2 in WT embryonic day 14 placentas generated from 
wild type intercrosses. In situ hybridization reveals that Ramp2 is robustly 
expressed in the labyrinth layer of the placenta. A) Lower magnification; scale 
bar = 100 microns. B) Higher magnification in the labyrinth; scale bar = 50 
microns. Inset images at both magnifications show sense control probes. cp = 
chorionic plate, lb = labyrinth, sp = spongiotrophoblast cells, dec = decidua; 
arrows point to giant trophoblast cells.  
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Figure 4.2 RAMP2 is essential for normal development of the labyrinth 
layer.  
Histology and IHC of embryonic day 14 placentas of WT and Ramp2-/- littermates 
generated from Ramp2+/- intercrosses. Hematoxylin and eosin stains reveal 
different layers of the placenta of WT (A) and Ramp2-/- (B) mice; L=labyrinth, 
J=junctional zone, D=decidua, scale bar = 1mm; Quantification of width of the 
labyrinth reveals no change between the WT (gray bar) and Ramp2-/- (black bar) 
placentas (C); However, labyrinth thickness is significantly decreased in Ramp2-/- 
placentas (black bar) compared to the WT littermate placentas (gray bar) with a p 
value <0.001 (D); Immunohistochemistry of WT (E) and Ramp2-/- (F) placentas 
using antibodies against pan-cytokeratin (green) marking trophoblast cells, scale 
bar = 500µm; Quantification of trophoblast cell counts in the labyrinth layer (G) 
shows a significant decrease in trophoblast cell number in Ramp2-/- placentas 
(black bar) compared to WT placentas (gray bar) with a p value <0.01. 
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Figure 4.3 Loss of RAMP2 results in a proliferation defect in the labyrinth 
layer.  
Immunohistochemistry of E14day placentas generated from Ramp2+/- intercross 
using antibodies against BrdU (white) and Ki67 (red, merge with DAPI is pink) to 
evaluate proliferation. Ramp2-/- placentas (B&D) show a remarkable decline in 
proliferation, primarily in the labyrinth region, compared to their controls (A&C), 
scale bars = 500µm; QRT-PCR revealed no significant changes between the WT 
(gray bar) and Ramp2-/- (black bar) placentas in apoptosis as measured by the 
ratio of anti-proliferative Bax and anti-apoptotic Bcl2 genes normalized to Gapdh 
(E).  
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Figure 4.4 Spiral artery defects in Ramp2-/- placentas.  
Immunohistochemistry of E14days placentas generated from Ramp2+/- 
intercrosses to evaluate spiral artery remodeling and uNK cell number. Staining 
of WT (A) and  Ramp2-/- (B) placentas with antibodies against smooth muscle 
actin revealed the presence of marked smooth muscle coverage (yellow) still 
remaining around spiral arteries in Ramp2-/- placentas, whereas WT littermate 
placentas have lost most of their smooth muscle coverage; scale bar = 100µm. 
DBA lectin staining of uNK cells (green) revealed no change in Ramp2-/- 
placentas (D) compared to their littermate controls (C), scale bar = 100µm; 
Quantification of uNK cell number from DBA lectin stained sections (E) revealed 
no change between the number of uNK cells between the WT (gray bar) and 
Ramp2-/- (black bar) placentas;  
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Figure 4.5 Loss of RAMP2 affects mRNA expression of RAMP2-interacting 
GPCRs.  
mRNA expression of RAMP2-interacting GPCRs from WT and Ramp2-/- 
placentas of E13.5 day; Pthr1 = parathyroid hormone receptor1, Calcrl = 
calcitonin receptor-like receptor, Ctr = calcitonin receptor, Gcgr = glucagon 
receptor, Vpac1r = vasoactive intestinal peptide receptor 1.  QRT-PCR analyses 
using TaqMan probes revealed a significant reduction in Pth1r levels in Ramp2-/- 
placentas (black bar) compared to the WT (gray bar) controls, a significant 
increase in Calcrl was observed in the knockout placentas (black bar) compared 
to the WT controls, p value < 0.01;  
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Figure 4.6 Loss of RAMP2 affects PTH1R protein expression and function  
A) Evaluation of PTH1R levels by immunoblotting in E 13.5day placentas from 
WT and Ramp2-/- mice reveals a modest reduction in PTH1R expression in tissue 
lysates from Ramp2-/- placentas compared to their controls; Each lane represents 
an individual placenta; GAPDH was used as the loading control. 
Immunohistochemistry using antibodies against PTH1R reveals a modest 
reduction of PTH1R-specific signal (red in B&C and white in D&E) in Ramp2-/- 
(C&E) placentas compared to their controls (B&D); scale bars = 100µm. 
Measurement of calcium content in the amniotic fluid of WT (gray bar) and 
Ramp2-/- (black bar) embryos reveals no change (F). QRT-PCR analyses 
revealed a significant increase in gene expression of plasma membrane calcium 
ATPase 1 (Pmca1) in Ramp2-/- placentas (black bar) compared to their WT (gray 
bar) littermate controls (H); p value <0.05.  
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Overview of results 
The goal of the research presented in this dissertation is to understand the 
physiological role of RAMP2 in the female endocrine system. To this end, we 
have employed a gene targeted mouse model of Ramp2. Previous studies from 
our laboratory have demonstrated that loss of Ramp2 results in midgestational 
embryonic lethality associated with abnormalities in the lymphatic vascular 
system (18). These studies have demonstrated an essential role for RAMP2 in 
embryonic vascular development. However, we were also interested in 
determining whether RAMP2 may play important physiological functions during 
adulthood. The research presented in Chapter 3 of this dissertation addresses 
the role of RAMP2 in adult mice, utilizing mice heterozygous for Ramp2. We 
have identified previously unknown functions of RAMP2 in the female endocrine 
system. In particular, we found that haploinsufficiency of Ramp2 in female mice 
leads to intrauterine growth restriction, fetal demise and severe postnatal 
lethality. Furthermore, we have shown that female Ramp2+/- mice develop mild 
hyperprolactinemia, hyperplastic anterior pituitary glands, precociously 
developed mammary glands and a poorly mineralized skeletal system.  It is 
important to recognize that these endocrine phenotypes are not observed in mice 
that are haploinsufficient for Adm or Calcrl; thus supporting the notion that 
RAMP2 has important physiological functions that extend beyond the canonical 
AM/CLR signaling paradigm.  Although the precise mechanisms underlying these 
endocrine phenotypes requires further investigation, our studies have 
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substantially driven the field forward by elucidating novel functions of RAMP2 in 
numerous endocrine organs. 
Additional studies, presented in Chapter 4, made use of tissues that are 
null for Ramp2, with the expectation that a complete absence of RAMP2 protein 
might exacerbate phenotypes and help lead to the discovery of novel RAMP2-
interacting GPCRs.  Indeed, we found that RAMP2 can alter the expression of 
the GPCR, PTHR1, in the Ramp2-/- placenta.  Specifically, loss of RAMP2 
reduced Pthr1 gene expression and PTHR1 protein expression in Ramp2-/- 
placental lysates, compared to littermate control placentas.  We also discovered 
marked defects in the development of the placenta including reduced labyrinth 
size, reduced cellularity and reduced proliferation of labyrinthine trophoblast 
cells.  Again, these phenotypes were not observed in Adm-/- and Calcrl-/- 
placentas.  More importantly, these phenotypes are consistent with the 
previously described function of PTHR1 signaling in regulating trophoblast cell 
proliferation. Therefore, our studies using placental tissue that is null for RAMP2 
provides the first in vivo evidence to support the biochemical studies that 
identified PTHR1 as a novel receptor partner for RAMP2.  Our results also 
suggest that RAMPs may regulate GPCR signaling, not only by regulating 
receptor trafficking and ligand binding specificity, but also by regulating GPCR 
transcription and protein levels.   
Collectively, the work presented in this dissertation has uncovered 
numerous physiological roles for RAMP2 in embryonic and placental 
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development, infertility and prolactin regulation, and in the development of the 
pituitary gland, mammary gland and the skeletal system.  
Future Directions 
The research presented in this dissertation has shed light on the 
numerous roles of RAMP2 in maintaining endocrine homeostasis in female mice. 
While these studies provide phenotypic characterization of Ramp2+/- female mice 
and Ramp2-/- placentas compared to their littermate controls, the specific 
receptor signaling mechanisms that were disrupted still remain to be elucidated. 
To address the potential mechanisms responsible for the observed phenotypes 
in Ramp2+/- mice, the following future directions can be taken: 
i) Generation and characterization of compound heterozygous mice of 
Ramp2 and the potential GPCR partners (Calcrl, Pthr1, Gcgr and Ctr) to evaluate 
if the phenotypes are conserved or exacerbated.  The rationale for this approach 
is that any moderate phenotypes that are elicited by haploinsufficiency of RAMP2 
may be exacerbated if and when the associating GPCR is also reduced by half.  
Additionally, because the RAMP2 phenotype is likely caused by altered signaling 
of numerous GPCRs in different tissues, a combinatorial approach may help 
distinguish phenotypes in an organ-specific way that can be related to the 
expression patterns of RAMP2-interacting GPCRs. 
In fact, phenotypic evaluation of gene targeted mouse lines for several of 
the RAMP2-interacting receptors has revealed numerous phenotypes (Table 
5.1), suggesting that a combinatorial breeding approach for generating 
compound gene targeted lines would likely result in alterations of phenotypes.   
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Of course, there are also several limitations to this approach, not the least 
of which are obtaining a large cohort of gene targeted mice from multiple 
investigators and establishing large breeding and phenotyping colonies.  
However, perhaps the more challenging aspect of this approach stems from what 
I have discovered as part of my thesis research regarding the strain-specific 
phenotypes of Ramp2 mice.  The studies presented in this dissertation made 
exclusive use of Ramp2 mice that were bred and maintained on an isogenic 
129/S6-SvEv genetic background.  The genetic robustness of using animals on 
an isogenic background is well-evidenced by the marked phenotypes which 
showed very little variability between individual animals.  However, during the 
course of my studies, I discovered that many of the endocrine phenotypes of 
Ramp2+/- mice are completely rescued when 129/S6-SvEv Ramp2+/- mice are 
bred onto a C57Bl/6 genetic background for one generation.  Clearly, the fact 
that a single back-cross onto a mixed genetic background can ameliorate many 
of the Ramp2+/- endocrine phenotypes observed on the 129/S6-SvEv genetic 
background demonstrates that there must exist potent genetic modifier alleles on 
the C57Bl/6 genetic background that modulate RAMP2 function.  (Of course, this 
in itself is an exciting discovery that warrants further exploration.)  However, 
within the context of the proposed approach of breeding Ramp2+/- mice onto mice 
with haploinsufficiency or deletion of several GPCRs, this strain-dependent 
phenotype of Ramp2+/- mice will likely introduce the caveat of genetic strain 
variation, making the correct interpretation of the findings very difficult. 
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 ii) Generate tissue-specific Ramp2 knockout mice that may survive 
beyond E14.5, to investigate a specific role for RAMP2 in organ development.  
During my thesis work, I have already made substantial progress toward this 
goal.  Specifically, I have designed and cloned a targeting vector for the 
conditional targeting of the Ramp2 locus, integrating loxP recombination sites 
within introns.  Briefly, the mouse Ramp2 knockout construct was generated by 
screening the 129S6/SvEv genomic library for phage clones containing the 5’ 
portions of the gene. By using suitable restriction sites within the genomic clone, 
5’ and 3’ regions of homology were subcloned into the multiple cloning site of the 
gene-targeting vector.  To achieve conditional deletion of Ramp2, loxP sites 
flanking exons 1 and 2 were inserted in the targeted vector. The same exons 
were deleted in the gene-targeted mouse model of Ramp2 that has been 
characterized in Chapters III and IV of this dissertation. Neomycin for positive 
selection and PGK-DTA (diphtheria toxin A) for negative selection were included 
in the vector as selection markers.  The final targeted vector was sequenced and 
verified to be accurate. 
Given the complex and robust phenotypes of Ramp2+/- mice in a variety of 
endocrine organs, a challenging next step in generating conditional Ramp2 
mouse lines is determining which tissue specific Cre line to use.  For example, 
while an osteoblast specific approach may be useful for better understanding the 
functions of RAMP2 in bone, a mammary gland specific deletion might be more 
valuable to understanding the role of RAMP2 in branching morphogenesis of the 
mammary epithelium.  However, an even more complex caveat to this approach 
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is the likelihood that the endocrine phenotypes of Ramp2+/- mice are inter-
connected.  For example, at this time, our studies do not rule out the possibility 
that the mammary gland and bone phenotypes of Ramp2+/- mice are coupled to 
the modest hyperprolactinemia that is elicited in the pituitary.  Therefore, 
choosing the appropriate tissue-specific approach to conditionally delete Ramp2 
in adult animals presents a challenging puzzle, for which a tremendous amount 
of resources and future studies will need to be dedicated before embarking on a 
particular cell or organ type. 
 iii) Generate a transgenic mouse line overexpressing Ramp2 exclusively 
in endothelial cells and then cross this line onto Ramp2+/- mice to eventually yield 
mice null for Ramp2 in all tissues except endothelial cells.  This approach builds 
upon our current understanding that the expression of Calcrl (and by extension, 
the expression of Ramp2) in developing endothelium is absolutely required for 
normal embryonic development, as observed by the phenotypes of mice with 
conditional Cre-loxP-mediated deletion of Calcrl in endothelium (18).  If we are 
able to replace the expression of Ramp2 specifically in endothelium of a Ramp2-/- 
mouse, then we may be able to generate a global Ramp2 null mouse that 
survives to adulthood by virtue of the expression of RAMP2 in the endothelium.  
Our prediction is that the endocrine phenotypes of the Ramp2+/- mice may be 
substantially exacerbated when the animal is bred to homozygosity. 
In fact, other members of the Caron laboratory are currently working 
towards the generation of an endothelial-specific Ramp2 transgenic mouse, with 
promising results.  Using the endothelial-specific VE-cadherin promoter, a 
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RAMP2 cDNA including an HA-tag was cloned downstream of the promoter, 
using conventional molecular biology approaches.  To date, several transgenic 
founder animals have been generated and we are currently evaluating these 
animals for expression and passage of the Ramp2 transgene onto offspring.     
An additional advantage to this approach is that several primary cell types null for 
Ramp2 could be isolated from the surviving adult mice.  For example, Ramp2-/- 
osteoblasts would be very beneficial for studying the role of Ramp2 on CTR and 
PTHR1 signaling while primary mammary epithelial cells could be used to 
elucidate the function of RAMP2 in PTHR1 signaling. 
 
Our studies suggest that PTHR1 function is compromised in Ramp2-/- 
placentas. In addition to lymphatic vascular abnormalities, perturbed PTHR1 
function may also contribute, at least in part, to the embryonic lethality in Ramp2-
/-
 mice. However, further studies employing both in vivo and in vitro approaches 
are needed to confirm that loss of RAMP2 and PTHR1 function results in 
placental dysfunction leading to fetal demise. To address this, the following future 
directions can be taken:  
i) Generation and characterization of compound heterozygous mice by 
crossing Ramp2+/- and Pthr1+/- mice (as suggested above). A phenocopy or 
exacerbation of placental abnormalities in the offspring null for Ramp2 and Pthr1 
would confirm our current observations and establish that PTHR1 and RAMP2 
form a functional receptor in a mouse placenta.  Additional further studies would 
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then attempt to determine if PTH, PTHrP or both ligands signal through PTHR1-
RAMP receptor complex. 
ii) Experiments involving the culturing of primary trophoblast cells null for 
Ramp2 are challenging due to the dramatically small litter sizes of Ramp2+/- 
intercrosses.  However, the isolation of Ramp2-/- trophoblast stem cell lines from 
Ramp2-/- blastocysts may be possible.  The Ramp2-/- trophoblast stem cells could 
then be differentiated along several trophoblast lineage pathways in culture and 
the extent of PTHR1 signaling could be evaluated in the absence of RAMP2. 
Moreover, microarray or proteomic approaches could be used to investigate 
pathways affected by loss of RAMP2. This approach would also shed light on the 
potential molecular players downstream of PTHR1-RAMP2 in trophoblast cells.  
iii) In vitro studies in trophoblast cell lines such as the human trophoblast 
cell line, HTR-8/Sv-Neo, to determine the influence of RAMP2 on downstream 
signaling of PTHR1 in response to PTH or PTHrP.  Indeed, during my thesis 
work, I have already made extensive use of the HTR-8/Sv-Neo trophoblast cell 
line to explore the potential functions of RAMP2 in PTHR1 signaling.  My current 
studies are focused on establishing the downstream signaling cascades that are 
activated by either PTH or PTHrP ligands in HTR-8/Sv-Neo cells.  Once these 
pathways are established for the HTR-8/Sv-Neo cell line, my hope is to perform 
siRNA-mediated knockdown of Ramp2 in order to determine whether the loss of 
RAMP2 influences PTHR1 signaling events in trophoblast cells.  These studies 
would help provide additional molecular insights into the potential cellular 
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mechanisms that underlie the trophoblast cell proliferation defects observed in 
Ramp2-/- placentas. 
A potential caveat to this approach is that the phenotypes of the Ramp2-/- 
placentas predominantly affect the trophoblast cells of the labyrinth lineage.  
However the HTR-8/Sv-Neo cell line represents a distinct and further 
differentiated trophoblast lineage that is more similar to the mouse trophoblast 
giant cell (invasive trophoblast cells that form the inner-most border of the 
maternal-fetal interface).  Since we do not yet have a full appreciation for the 
expression pattern or function of PTHR1 signaling in different trophoblast 
lineages, we cannot exclude the possibility that results obtained from HTR-8/Sv-
Neo cell lines may not be directly applicable to the observed in vivo phenotype 
involving labyrinthine trophoblast cells.  Unfortunately, robust labyrinthine 
trophoblast cells that can be easily transfected do not, to my knowledge, 
currently exist.  Nevertheless, a focused evaluation of the function of RAMP2 in 
PTHR1 signaling of trophoblast cells is highly warranted. 
iv) Determine whether Pthr1 gene expression and protein levels are 
regulated directly by RAMP2.  An interesting, and somewhat unexpected finding 
of my thesis work is that the gene expression and protein levels of Pthr1 are 
markedly reduced in Ramp2-/- placentas.  A potential explanation for this finding 
is that the reduction in labyrinthine trophoblast cells results in reduction of 
PTRH1 expression, by virtue of the fact that PTHR1 is expressed in this 
trophoblast lineage.  However, an alternative explanation is that RAMP2 has 
important functions in regulating the gene expression and protein levels of its 
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associating GPCRs.  Our laboratory has already uncovered homeostatic 
compensations of GPCRs in response to changes in Ramp gene expression.  
For example, the expression of Calcrl is modestly, yet significantly, increased in 
the hearts of mice that are null for Ramp3.  While this data suggests a 
compensatory or homeostatic mechanism for regulating Calcrl signaling, the 
possibility that the mRNA and protein expression of other GPCRs is directly 
modulated by RAMP proteins is novel, exciting and worth pursuing.      
 
Clinical implications of RAMP2 
 RAMP2 could be a viable target for diseases such as hyperprolactinemia, 
osteoporosis and infertility. Although dopamine agonists are the first line of 
treatment of hyperprolactinemia, the numerous side effects of dopamine based 
treatment (96) such as nausea, vomiting, headache, dizziness, drowsiness and 
other rare complications affecting the lung and heart function (97), keep the 
search ongoing for developing a more suitable drug.  
Interestingly, treatment of osteoporosis also remains challenging. The 
presence of RAMPs in osteoblasts (98)) and osteoclasts (99), as well as 
osteoporosis-like phenotypes in Ramp2+/- (25) and Amy+/- (100) mice suggest 
that targeting RAMP2, perhaps at the CTR-RAMP2 interface, might be beneficial 
in treating conditions such as osteoporosis. Lastly, our work has demonstrated 
that RAMP2 has implications in pregnancy in mice; playing crucial roles in fetal 
growth, placental development and postnatal growth of pups. Therefore, RAMP2 
needs to be exploited for its role in the successful outcome of a pregnancy. Since 
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we lack knowledge about the precise GPCRs, besides CLR, that might be 
involved in the RAMP2-mediated functions in the female reproductive system, 
future studies addressing these gaps in our understanding would become 
extremely important. Additionally, the fact that multiple organ systems can be 
affected by the deficiency or the complete absence of RAMP2 has to be taken 
into consideration when creating a therapeutic against RAMP2, in order to 
develop a drug with greater specificity.  
 
Conclusions 
In summary, the findings presented in this dissertation have significantly 
advanced the field of RAMP research by providing an in vivo model that supports 
previously reported biochemical investigations. In addition, as reviewed in 
Chapter 2 and as shown in Fig 5.1, this dissertation provides a summary of the 
phenotypes of gene targeted mouse models of all the RAMPs. More importantly, 
the phenotypic characterization of a mouse model of Ramp2 presented in 
Chapters 3 and 4 have provided novel insights on the role of RAMP2 in 
postnatal development as well as a role in placentation. Furthermore, these 
studies enhance our understanding of the in vivo role of Ramp2 and should bear 
significance in the development of RAMP2-based therapeutics.  
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Knockout 
Phenotype Adrenomedullin
Calcitonin 
receptor-like 
receptor
Parathyroid 
hormone
Parathyroid 
hormone related 
peptide
Parathyroid 
hormone 
receptor 1
Glucagon Glucagon                       Receptor Amylin
Calcitonin 
Receptor RAMP2
Embryonic 
lethality
Midgestational 
lethality
Midgestational 
lethality Viable Perinatal lethality
Midgestational 
lethality Postnatal lethality
Late-gestational  
to perinatal 
lethality
Viable Midgestational lethality
Midgestational 
lethality
Female   
Fertility
Heterozygotes 
are subfertile
Heterozygotes     
are subfertile Normal
Heterozygotes are 
fertile
Heterozygotes 
are fertile Normal
Subfertility; 
perinatal and 
postnatal lethality 
in pups born to 
Kos.
Normal
Heterozygotes     
are subfertile 
(unpublished)
Severe subfertility in 
heterozygotes
Placenta
Defective with 
failure of spiral 
artery 
remodelling
Phenocopy AM-/- 
placentas
Placental calcium 
transfer normal; 
reduced expression 
of TRPV6, calbindin 
D-9K, and VDR.
Impaired 
intraplacental yolk 
sac; increased 
placental calcium 
transfer
Decreased 
placental calcium 
transfer
Not described
Impaired glucose 
transport;                      
fetal growth 
restriction
Not described Not described
Proliferative defect in 
labyrinthine 
trophoblasts and 
failure of spiral artery 
remodeling
Prolactin
No change in 
basal serum 
(unpublished); 
not tested during 
pregnancy
No change in 
basal serum 
(unpublished); 
not tested during 
pregnancy
Not described Not described Not described Not described Not described Not described Normal  (unpublished)
Mild 
hyperprolactenemia 
(basal & during 
pregnancy) in 
heterozygotes 
Pituitary 
gland Not described
Normal 
(Unpublished) Not described Not described Not described Not described Not described Not described Not described
Heterozygotes exhibit 
anterior pituitary 
gland hyperplasia
Mammary 
gland
Mild hypoplasia 
(unpublished)
Mild hypoplasia 
(unpublished) Not described
Failure to form 
mammary 
epithelial duct
Phenocopy Pthrp -
/
-
 mice
Not described Not described Not described Not described Heterozygotes have precocious branching
Serum 
Calcium Not described Not described Hypocalcemia Hypocalcemia Hypocalcemia Not described Not described Not described Normal Normal
Bone Not described Not described
Reduced cartilage 
mineralization and 
enhanced bone 
mineralization
Accelarated 
differentiation of 
chondrocytes of 
the growth plate
Phenocopy Pthrp -
/
-
 mice
Not described Not described
Low bone mass 
due to icreased 
resorption in 
heterozygotes
Increased bone 
mass due to 
icreased bone 
formation
Reduced 
minrealization in the 
heterozygotes
Table 5.1 Phenotypes of Mouse Models of RAMP2-interacting GPCRs and their ligands 
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Figure 5.1 Summary of phenotypes of gene targeted mouse models of 
RAMPs 
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